The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2019

DEVELOPMENT OF AUTOMATED RADIOTHERAPY TREATMENT
PLANNING FOR CERVICAL AND BREAST CANCER FOR
RESOURCE-CONSTRAINED CLINICS
Kelly Kisling

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, and the
Radiation Medicine Commons

Recommended Citation
Kisling, Kelly, "DEVELOPMENT OF AUTOMATED RADIOTHERAPY TREATMENT PLANNING FOR CERVICAL
AND BREAST CANCER FOR RESOURCE-CONSTRAINED CLINICS" (2019). The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses
(Open Access). 924.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/924

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

DEVELOPMENT OF AUTOMATED RADIOTHERAPY TREATMENT PLANNING FOR CERVICAL AND BREAST
CANCER FOR RESOURCE-CONSTRAINED CLINICS

By
Kelly Kisling, M.S.

APPROVED:

______________________________
Laurence E. Court, Ph.D.
Advisory Professor

______________________________
Peter A. Balter, Ph.D.

______________________________
Rebecca M. Howell, Ph.D.

______________________________
Anuja Jhingran, M.D.

______________________________
Kathleen Schmeler, M.D.

____________________________________________________________________________________
APPROVED:

______________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

DEVELOPMENT OF AUTOMATED RADIOTHERAPY TREATMENT PLANNING FOR CERVICAL AND BREAST
CANCER FOR RESOURCE-CONSTRAINED CLINICS

A
DISSERTATION
Presented to the Faculty of
The University of Texas
MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY

by
Kelly Kisling, M.S.
Houston, Texas
May, 2019

Acknowledgments
I am grateful to have so many people to acknowledge who have contributed to this work and to my
development as a researcher. First, I would like to thank my advisor, Dr. Laurence Court for his
unwavering optimism and encouragement that undoubtedly kept me moving forward through the
difficult aspects of this project. He has a gift for cultivating an environment of scientific curiosity and
critical thinking. Also, his passion for creating meaningful change is a source of inspiration.
I would also like to thank my advisory committee (Drs. Peter Balter, Rebecca Howell, Anuja Jhigran,
and Kathleen Schmeler) whose guidance and interest in my research have been critical. I would like to
especially acknowledge Dr. Howell, who was also my advisor for my MS research. She is a fantastic role
model, teacher, and advisor who always pushes for the best interest of her students and for the best
work out of them.
I would also like to acknowledge the current and former members of my lab group, from whom I
have learned some of my most valuable lessons of grad school: Brian Anderson, Dr. Carlos Cardenas, Dr.
Xenia Fave, Dr. David Fried, Skylar Gay, Dr. Rachel Ger, Dr. Scott Ingram, Dr. Yuting Li, Dr. Dennis
Mackin, Dr. Rachel McCarroll, Tucker Netherton, Dr. Calli Nguyen, Dr. Josh Niedzielski, Constance
Owens, Deborah Raffetto, DJ Rhee, Dr. Yvonne Roed, Dr. Ashley Rubinstein, and Dr. Jinzhong Yang. I
have been inspired by their curiosity, insistence on scientific rigor, and staunch opinions on the best
way to communicate research.
There are many other staff and faculty at MD Anderson with whom I have collaborated in this work
and who have provided me with mentorship. There are many wonderful medical physicists, physicians,
and dosimetrists in the Department of Radiation Oncologist who have taken time to discuss clinical
matters with me and thoughtfully answered my multitude of questions. Namely, Dr. Simona Shaitelman
who has graced me with not only her wisdom in radiotherapy of breast cancer, but also in career
advice. Also Dr. Anuja Jhingran who has mentored me in pursuing research in global health and shared
her expertise in radiotherapy of cervical cancer. I would like to acknowledge Dr. Beth Beadle for always
iii

giving me thoughtful feedback on the tools I am developing, guiding the integration of my work into the
bigger picture of automated planning, and being a great travel partner. I would especially like to thank
Dr. Joy Zhang, who has patiently mentored me in the development of software and provided
encouragement and friendship from the very start of my PhD. She is a brilliant woman whose work
ethic is unmatched, and I was lucky to have gotten to collaborate with her so closely on this project!
I have been fortunate to be able to work on this project with collaborators across the globe.
Without them, this project would have gone nowhere and would not have the promise of making a
real, meaningful impact on the state of radiotherapy globally. I would like to thank Dr. David Anderson,
Kobus Botha, Hester Burger, Monique du Toit, Dr. Nazia Fakie, Dr. Hannah Simonds, Christoph
Trauernicht, and many more people at Groote Schuur and Tygerberg Hospitals.
I owe special thanks to my wonderful family for their love and support throughout my life. Thank
you to my parents, Doug and Karrie Kisling, who have encouraged us to be independent, strong-willed,
and adventurous women, and who have set an example for how hard work truly pays off. And thank
you to my big sisters, Amy Kisling and Carter Bisso, for being fantastic role models and friends.
Finally, I cannot fully express the appreciation and gratitude I have for Tom Appleman, my partner
in life and outdoor adventures. From the beginning has he provided me with unfailing support for my
career and life aspirations and has been a source of strength during the hard days of my PhD. Tom,
along with our dog Maple, has made all the small and large moments in between working on this PhD
so wonderful. I couldn’t imagine a better teammate in life, and am excited for our next chapter, and all
the rest to follow. Thank you, Tom.

Acknowledgment of Support: I would like to thank the NIH for funding this work (National Institutes of
Health/National Cancer Institute grants UH2-CA202665 and UH3-CA202665) and Varian and Mobius
Medical systems for providing support for this work.
iv

DEVELOPMENT OF AUTOMATED RADIOTHERAPY TREATMENT PLANNING FOR CERVICAL AND BREAST
CANCER FOR RESOURCE-CONSTRAINED CLINICS

Kelly Kisling, M.S.
Advisory Professor: Laurence Court, Ph.D.

Globally, cancer rates are on the rise, especially in low- and middle-income countries (LMICs).
However, many of these countries lack access to radiotherapy, which is due in part to a substantial
shortage of the staff necessary to deliver safe and effective radiotherapy. This staff shortage could be
mitigated by the automation of the radiation treatment planning process. To this end, we developed
automated planning for cervical and postmastectomy breast cancer radiotherapy, the two most
common types of cancer in women in many LMICs.
For radiotherapy of cervical cancer in resource-constrained clinics, the recommended treatment
technique is a four-field box. We created algorithms to plan four-field box treatments with
homogenous dose distributions by automatically determining the beam apertures and relative beam
weights. Using our techniques we automatically planned 150 four-field-box treatments and 89% were
scored acceptable by radiation oncologists. The dose distributions were more homogenous (p<0.001)
using automatically optimized beam weights compared with equal beam weights. We also created an
automatic quality assurance (QA) technique to verify the clinical acceptability of the beam apertures,
which flagged 90% of the unacceptable beam apertures (false-positive rate: 16%).
For radiotherapy of node-positive, postmastectomy breast cancer, it is recommended to treat the
chest wall and ipsilateral nodes, while reducing the dose to normal tissues, such as the heart and lungs.
We created algorithms to plan three-field treatments (mono-isocentric tangential and supraclavicular
fields) on free-breathing patient CTs. The dose distribution was automatically optimized by using mixed
energy photon beams and field-in-field dose modulation. Using these algorithms, we automatically
planned radiotherapy treatments for 10 left-sided, postmastectomy patients. The plans were evaluated
v

quantitatively based on their dose distributions, and 90% of the plans met constraints for lung dose,
heart dose and target coverage. Physicians accepted all plans either as-is (50%) or with only minor
changes (50%). Automatic QA of the plans flagged 92% of the changes requested by physicians.
To assess the risk of failure in our automated treatment planning workflow, we performed Failure
Modes and Effects Analysis (FMEA). FMEA showed that a specially-designed automated QA program
reduced the risk of automated treatment planning. Additionally, we found that human error is still a
prominent cause of potential failures and that manual plan reviews of automatically generated plans
are still vital for safe delivery of radiotherapy.
In conclusion, automated treatment planning and QA for radiotherapy of cervical and breast
cancers were clinically viable for a majority of patients tested. Our algorithms will be implemented
clinically at our partner hospitals in South Africa in the next year.
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Chapter 1 : Introduction

1.1 Prevalence of cervical and breast cancer
The majority of the global cancer burden is in low- and middle-income countries (LMICs), where
two-thirds of all cancer deaths in the world occur [1]. This amounts to more than eight million cases of
cancer and five million deaths from cancer each year in a part of the world that has few resources to
fight the disease [1]. Furthermore, cancer rates are on the rise, and the number of cases worldwide is
predicted to rise from 14 million to 20 million cases of cancer each year by 2025 [2]. This rate of
increase is expected to be the most rapid in LMICs [2].
Breast and cervical cancers are extremely prevalent in LMICs, where they are the first and second
most common types of cancer occurring in women [1]. They are also the first and third most common
cause of cancer death for women in these regions [1]. More than half of all breast cancers occur in the
developing world, where a large proportion of cases are detected in late stages [3]. A large majority of
cervical cancer deaths (87%) occur in LMICs, where the risk of dying from the disease is three times
higher than in more developed regions [1].

1.2 Radiotherapy for cervical cancer
For locally advanced cervical cancer (stages IB2–IVA), the standard of care treatment is concurrent
chemotherapy and radiation, including both external beam radiotherapy and brachytherapy [4]–[9].
The goal of the external beam radiotherapy is to treat the gross tumor and any at-risk tissues in the
pelvis, including lymph nodes and paracervical tissue, which reduces the risk of regional spread and the
volume of the gross tumor prior to brachytherapy. Overall, radiotherapy has been shown to greatly
improve local control of cervical cancer [4]–[9].
There are several primary techniques used to deliver external beam radiotherapy for cervical
cancer: conventional, using two to four fields based on the bony anatomy; conformal, using two to four
1

fields that are designed on the basis of soft tissue contours within the pelvis; and intensity-modulated
radiotherapy (IMRT), using five or more fields that are inversely-optimized on the basis of soft tissue
contours within the pelvis. The selection of which treatment technique to use depends on the clinical
resources available, the dose to normal tissues, and organ motion within the treatment area. The
conventional technique is recommended for the treatment of locally advanced cervical cancer in
resource-constrained clinics by both the American Society of Clinical Oncology (ASCO) and the
International Atomic Energy Agency (IAEA) [10], [11]. The conventional technique uses considerably
less resources than both the conformal and IMRT techniques which rely on accurate contouring.

1.3 Radiotherapy for breast cancer
For many stages of breast cancer, radiation is essential for treatment after surgery (lumpectomy or
mastectomy). In more advanced stages of the disease, as is common in LMICs, the surgical procedure is
usually a mastectomy. If the axillary lymph nodes are found to be involved, radiotherapy of the chest
wall and at-risk lymph nodes is the standard treatment and has been shown to reduce the risk of local
recurrence and improve survival among these patients [12]–[15]. The targeted lymph nodes include the
level III axillary and supraclavicular (SCV) lymph nodes, and sometimes also include the internal
mammary chain (IMC) lymph nodes. Including the IMC lymph nodes in the radiotherapy treatment
increases the complexity of the radiotherapy and may increase the dose to sensitive normal tissues,
such as the heart [16]. Given that the treatment of the IMC lymph nodes remains controversial, they
may not be included if there is no indication that these nodes might be involved [17]. In resource
constrained settings, the IMC lymph nodes are commonly not treated, as they do not have access to
specialized techniques that help reduce heart dose by delivering the radiation to the patient under
deep inspiration breath hold.
One of the most common techniques for the treatment of node-positive, postmastectomy breast
cancer is a tangential pair of fields, for treating the chest wall, which is matched to an anterior-oblique
2

field, for treating the SCV lymph nodes. The goal of this technique is to treat the entire chest wall and
at-risk lymph nodes (SCV and level III axillary), while minimizing dose to sensitive normal tissues, such
as the lung and heart [18]–[21]. Additionally, studies have shown that using radiotherapy techniques
which achieve a homogenous dose can significantly reduce painful acute skin reactions [22]. There are a
few techniques employed in order to achieve a homogenous dose, including using a combination of
high and low energy photon beams and various field modulation techniques, such as wedges or field-infield (FIF) segments.

1.4 Radiotherapy resources in low- and middle-income countries
Radiation therapy is an essential aspect of the treatment for cancer: approximately half of all
cancers require radiation therapy as part of their treatment [23]. Yet in low- and middle-income
countries, radiation therapy is only accessible to half the number of people who need it [23]. One of the
major contributing factors to the lack of radiotherapy access in less-developed regions is an enormous
shortage of specialized radiotherapy staff [24]. Staff shortages in resource-constrained radiotherapy
clinics have led to the use of simplified treatment techniques that require less time to plan than
modern treatments, but can result in inferior outcomes. The time that staff spend planning treatments
has been identified as a major contributor to the cost of radiation therapy for low- and middle-income
countries [25]. Shortening, or eliminating, the time required to plan treatments could reduce this huge
deficit in radiotherapy staff. As a result, we could lower the cost of radiation therapy.

1.5 Automation in Treatment Planning
Currently, treatment planning is a time-intensive, manual process that is necessary for delivering
high quality radiation therapy to every patient. The process of treatment planning can be broken down
into three general steps: (1) designing the treatment beam geometry, (2) optimizing the dose
distribution delivered by the beams, (3) and quality assurance checks verifying the appropriateness and
3

safety of each treatment plan. These steps involve major human input from specialized staff, and in
order to automate this process, we need to develop and validate novel automation techniques that will
replace every manual step of treatment planning.
While work has been done towards automating some of the individual steps of planning, the focus
has been to ease workflows in high-resource clinics such as those in the United States. Many of these
have focused on automated optimization of inversely-planned treatments, such as IMRT [26]–[29].
However, there are many other manual steps that would need to be completed in order to plan these
treatments. For breast cancer, there has been some work towards automation of planning for
individual process steps or for a simpler radiotherapy technique which is used for earlier stages of the
disease [30]–[34]. However, given the prevalence of more advanced stages of breast cancer in LMICs, a
more complex treatment technique is needed but has not yet been automated. There has never before
been a concerted effort to develop a fully-integrated automated planning solution that requires no
additional inputs from staff for cervical cancer or node-positive, postmastectomy breast cancer.

1.6 Study Goal
The overall objective of this project was to automate treatment planning of radiotherapy for
patients with locally advanced cervical cancer and node-positive, postmastectomy breast cancer,
including automated verification of plan quality. We validated the techniques that we developed and
integrated them as a fully automated planning tool. Our goal was to require only a computed
tomography (CT) scan and prescription as input, and with no other human interaction, generate a
patient-specific treatment plan.
In order to determine if the plans generated by the fully automated planning tool were acceptable
for treatment, we tested the system retrospectively using patient CT datasets from several institutions,
including MD Anderson and our partner hospitals located in South Africa. The resulting treatment plans
were evaluated by radiation oncologists from several institutions in both South Africa and the United
4

States. Finally, we created and test techniques to reduce the risk of automated planning by
automatically detecting when plans are not of acceptable quality.
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Chapter 2 : Purpose and Central Hypothesis
Central Hypothesis:
We hypothesized that 90% of the treatment plans created with our automated planning techniques will
be rated as clinically acceptable by radiation oncologists and that our automated quality verification
techniques will detect 90% of unacceptable plans.

Specific Aim 1:
Aim: Develop automated treatment planning of radiotherapy for patients with locally advanced cervical
cancer.
Hypothesis: Treatments planned by our automation techniques would be rated as clinically acceptable
by radiation oncologists for at least 90% of plans.
Aim 1.1: Automated design of the beam apertures.
Aim 1.2: Automated optimization of the beam weights.
The work towards Specific Aim 1 is presented in Chapter 3: Automated Treatment Planning for
Radiotherapy of Locally Advanced Cervical Cancer.

Specific Aim 2:
Aim: Develop automated treatment planning of radiotherapy for patients with node-positive,
postmastectomy breast cancer.
Hypothesis: Treatments planned by our automation techniques would be rated as clinically acceptable
by radiation oncologists for at least 90% of plans.
Aim 2.1: Automated design of the treatment field geometry.
Aim 2.2: Automated optimization of the dose distribution.
The work towards Specific Aim 2 is presented in Chapter 4: Automated Treatment Planning for
Radiotherapy of Postmastectomy Breast Cancer.
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Specific Aim 3:
Aim: Assess the risk of automated treatment planning and develop automated quality verification
techniques for treatment plans resulting from Aims 1 and 2.
Hypothesis: Our quality verification techniques would automatically detect 90% of plans with
unacceptable plan quality.
Aim 3.1: Assess the risk of automated planning.
Aim 3.2: Develop automated quality assurance (QA) for cervical cancer automated planning.
Aim 3.3: Develop automated QA for breast cancer automated planning.
The work towards Aim 3.1 is presented in Chapter 5: Assessment of Risk in Automated Treatment
Planning.
The work towards Aim 3.2 is presented in Chapter 6: Automated Plan Quality Verification for Cervical
Cancer Radiotherapy.
The work towards Aim 3.3 is presented in Chapter 4: Automated Treatment Planning for Radiotherapy
of Postmastectomy Breast Cancer.
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Chapter 3 : Automated Treatment Planning for Radiotherapy of Locally Advanced
Cervical Cancer
This chapter is based upon the following article:
Kisling K, Zhang L, Simonds H, Fakie N, Yang J, McCarroll R, Balter P, Burger H, Bogler O, Howell R,
Schmeler K, Mejia M, Beadle BM, Jhingran A, Court L. Fully automatic treatment planning for external
beam radiation therapy of locally advanced cervical cancer – a tool for low-resource clinics. J Glob
Oncol, no. 5. 2019:1-9. doi:10.1200/JGO.18.00107

3.1 Introduction
Global cancer rates are increasing, especially in low- and middle-income countries [1]. By 2025, 20
million cancer cases are predicted worldwide annually [2], of which half would benefit from treatment
with radiation therapy [23], [35], [36]. However, many countries lack adequate radiation therapy
capabilities [23]; this is due, in part, to staff shortages in these regions [24]. Automating radiation
treatment planning could help mitigate this limitation by allowing technology to do a large part of the
required work to begin treatment of patients. In addition, an expedited planning process could enable
patients to be treated much sooner after diagnosis. According to ASCO and the International Atomic
Energy Agency, the recommended treatment of invasive cervical cancer in low-resource settings is a
radiotherapy technique known as a “four-field box” [10], [11]. This technique uses four orthogonal
beams to treat the gross tumor and at-risk tissues in the pelvis. The beam apertures are based on bony
anatomy that is visible in a digitally reconstructed radiograph from each of the beam angles:
anteroposterior, posteroanterior, right lateral, and left lateral. Examples of beam apertures are shown
in Figure 1.
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Figure 1. Automatically created treatment fields. Beam’s eye view of the (A) anteroposterior (AP) and
(B) right lateral beam angles. The beam apertures are designed on the basis of the bony anatomy and
will be collimated using the multileaf collimator.
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Through a collaboration with hospitals in South Africa and the United States, we have developed a
fully automatic treatment planning tool, the Radiation Planning Assistant (RPA) [37]. The RPA designs
patient-specific four-field box radiation treatments for locally advanced cervical cancer, one of the most
prevalent forms of cancer in low-resource settings [1]. To build the RPA, we developed algorithms to
automate every step in the treatment planning process. The RPA has been integrated with a
commercial treatment planning system (TPS) to plan three-dimensional treatments on planning CT
scans with no human input.
The objective of this study was to validate the individual algorithms of the RPA and to test the fully
integrated system on patient CT scans. We retrospectively tested the RPA using patient CT scans from
cancer hospitals in the United States and in South Africa. We have also implemented a semiautomated
version of the RPA into the clinical workflow at The University of Texas MD Anderson Cancer Center
(Houston, TX; hereafter, MD Anderson).

3.2 Methods
All studies and patient data were handled in accordance with the corresponding approved
institutional review board protocol, and where required, patient consent was obtained.
3.2.1 Overview of the RPA
To plan a patient-specific treatment with the RPA, the following inputs are used: (1) a CT scan of
the patient in the treatment position and (2) a plan order from the physician, which includes basic
patient information, including the prescription. With no further human input, the RPA automatically
creates a treatment plan that is ready for physician review, along with plan documentation. This
documentation is for the patient’s medical record and for performing quality assurance checks that are
vital to delivering safe radiotherapy [38]. The documentation includes all dose distributions, allowing
the physician to review the quality of the plan, including target coverage.
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Algorithms have been developed to automate each manual step of treatment planning and have
been integrated with the Eclipse TPS (Varian Medical Systems, Palo Alto, CA) using its Application
Programming Interface to form the fully automatic TPS. The algorithms that automate each step are
described in the following section.
3.2.2 In-House Automation Algorithms
3.2.2.1 Delineation of the body contour
The body contour (Figure 2) is important for accurate dose calculation in the Eclipse TPS. The first
step in this algorithm is to identify the location of the couch using the sum projection signal along the
lateral direction and then searching for the most representative peak. The couch is then removed from
the image by setting all pixels posterior to this line to the CT number of air. The RPA then searches for
the body contour by thresholding the CT image intensity (with the couch removed) into a binary mask;
it then uses postprocessing to ensure the topologic characteristics and smoothness.

Figure 2. Body contour and marked isocenter. (A-C) Three views, (A) axial, (B) sagittal, and (C) coronal,
of the computed tomography scan of a patient. The automatically segmented body contour is outlined
in red. The views intersect at the location of the marked isocenter (green), which is determined on the
basis of the radiopaque external fiducials. The intersecting planes are denoted by the dashed yellow
line.
3.2.2.2 Detection of the marked isocenter
The next step in the RPA is to automatically detect the marked isocenter, as indicated by the
intersection of three radiopaque fiducials placed on the patient’s skin during the planning CT scan
(Figure 2). The RPA automatically detects the marked isocenter by defining a search domain within the
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bandwidth of the body contour. Potential fiducial candidates within the search domain are identified on
the basis of the CT number. Any false candidates are removed using several criteria, including size,
location, and geometry. Finally, the intersection of the selected cluster of three fiducials is used to
define the marked isocenter.
3.2.2.3 Design of the treatment field apertures
The RPA then automatically designs the four orthogonal treatment beams, which intersect at the
marked isocenter. First, the RPA automatically segments the following bony anatomy on the CT image:
bony pelvis, femoral heads, sacrum, and fourth and fifth lumbar vertebral bodies. The RPA uses a
deformable, multiatlas technique for automatic segmentation [39], [40]. Next, the RPA projects the
segmented anatomy into each beam’s eye view (BEV). The RPA automatically identifies anatomic
landmarks in the BEV, such as the widest extent of the pelvic inlet, and sets the beam aperture on the
basis of these landmarks according to a set of defined rules (eg, 2 cm wider than the pelvic inlet). A
representation of this workflow is shown in Figure 3.

Figure 3. Workflow of the algorithm that automatically designs four-field box treatment beams. For
automated planning, the only input is a computed tomography scan and a prescription. No other
human input is required, and a plan is presented for physician review. 2D, two dimensional; 3D, three
dimensional; BEV, beam’s eye view
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3.2.2.4 Optimization of the dose distribution
Next, the RPA creates the treatment beams in the Eclipse TPS using the automatically defined beam
apertures set at the automatically located isocenter. The RPA then automatically calculates the dose
delivered by each beam using 18-MV photons. To achieve a homogenous dose distribution within the
treated volume, the RPA automatically determines the weighted contribution of each beam. The RPA
uses a least-squares fitting to determine the beam weights that minimize the dose heterogeneity inside
the treated volume. The treated volume is defined as the volume intersected by all beams, contracted
by a 0.5-cm margin to exclude the rapid dose drop-off at the field edge.
3.2.3 Retrospective Testing of RPA Algorithms
We first tested each algorithm retrospectively on 150 pelvic CT scans of female patients at MD
Anderson. Then we tested the fully integrated RPA on 10 CT scans of female patients from Tygerberg
Hospital (Cape Town, South Africa) and four CT scans from Groote Schuur Hospital (Cape Town, South
Africa). All CT scans had been acquired for radiotherapy planning, with the patients supine.
3.2.3.1 Delineation of the body contour
The automatically delineated body contour from the RPA was compared with the body contour
resulting from Eclipse’s semiautomated body contour tool, with manual edits where necessary. The two
body contours were compared quantitatively using the Dice similarity coefficient, mean surface
distance, and Hausdorff distance [39].
3.2.3.2 Detection of the marked isocenter
The automatically localized marked isocenter was compared with an isocenter that had been
manually placed at the intersection of the three fiducial markers. The absolute distance between these
two points was calculated and used for comparison.
3.2.3.3 Design of the treatment-field apertures
The automatically created treatment-field apertures were reviewed by two physicians specializing
in gynecologic radiation oncology, one from MD Anderson (A.J.) and one from Tygerberg Hospital in
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South Africa (H.S.). They rated each field as “acceptable” or “not acceptable” for treatment, on the
basis of whether they would treat the patient using that field. For a plan to be acceptable, all four fields
must have been rated as acceptable.
3.2.3.4 Optimization of the dose distribution
The dose distributions were calculated using automatically optimized beam weights and were
compared with nonoptimized dose distributions, which used equally weighted beams (ie, each beam
contributed the same dose to the calculation point). The maximum dose, defined by the hottest 1 cc of
tissue, was evaluated. We also assessed the coverage, defined by the percentage of the treated volume
covered by at least 95% of the prescription dose. The values with and without automated beam weight
optimization were compared using a Wilcoxon signed-rank test.
3.2.3.5 Running time of the RPA system
The time for the RPA to automatically plan a treatment was recorded. This included every step,
beginning from the import of the CT scan and plan order into the RPA and ending with the optimized
and calculated treatment plan in the TPS, ready for physician review.
3.2.3.6 Running the RPA remotely on patients at two South African hospitals
The fully integrated RPA was tested on-site at Tygerberg Hospital and Groote Schuur Hospital. The
resulting treatment plans and dose distributions were reviewed by physicians specializing in
gynecologic oncology at the corresponding hospital (H.S., N.F.) and rated as acceptable or not
acceptable for treatment.
3.2.4 Clinical Deployment at MD Anderson
A semiautomated version of the RPA was created and deployed into the clinical workflow at MD
Anderson for patients with cervical cancer in July 2016. This version was integrated with the Pinnacle
TPS (Philips Healthcare, Andover, MA). The workflow of this system differs from the fully automated
workflow in that the physician manually contours the soft-tissue target volumes on the CT scan. After
the CT scan is imported into the TPS, the dosimetrist exports the CT scan to the RPA, The RPA then
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automatically detects the marked isocenter and designs the treatment-field apertures (still based on
the bony anatomy). Once complete, the RPA automatically sends an e-mail indicating that the plan is
ready, and the dosimetrist imports the uncalculated treatment beams. The physician reviews the
beams, making any necessary edits on the basis of the contours of the target and critical structures, and
planning continues.
We assessed any manual changes to the location of the marked isocenter. We also quantitatively
compared the extent of the physician edits to the automatically planned beam apertures, using the
mean surface distance and Hausdorff distance.

3.3 Results
3.3.1 Retrospective Testing of RPA Algorithms
3.3.1.1 Delineation of the body contour
A typical result of the automatically delineated body contour is shown in Figure 2. This body
contour agreed well with the contour generated using Eclipse’s semiautomatic tool with manual edits.
The median Dice similarity coefficient was 0.996 (standard deviation [SD], 0.001; range, 0.988 to 0.997).
The median mean surface distance was 0.6 (SD, 0.2; range, 0.4 to 1.9) mm. The median Hausdorff
distance was 22.3 (SD, 18.6; range, 5.7 to 122.7) mm.
The largest discrepancies were found when the patient’s arm was included in only one of the
contours. Although these differences may seem large in some patients, they result from differences in
how each technique handled the inclusion of the patients’ arms. These discrepancies are outside the
treatment area and would not affect the dose delivered.
3.3.1.2 Detection of the marked isocenter
The distances between automatically and manually placed marked isocenters were small (average,
1.1 mm; SD, 0.7; range, 0.1 to 2.9 mm). The largest discrepancies were found when the fiducials did not
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all appear on the same axial slice of the patient’s CT scan. This sometimes led to the isocenters being
located on adjacent slices.
3.3.1.3 Design of the treatment-field apertures
An example of the treatment fields generated by the RPA are shown in Figure 1. Of the 150
treatment plans (n = 600 fields), one physician rated 136 (91%) as acceptable for treatment. The second
physician found that the image quality of the BEV was too poor in six of 150 plans (four had large
amounts of bowel contrast that partially obstructed the bony anatomy in the BEV) and did not rate
these six plans. Of the remaining 144 plans, the physician rated 126 (88%) as acceptable. Of the plans
marked as unacceptable by at least one physician (n = 23), 19 (83%) had incorrectly placed superior
borders as a result of inaccurate contouring of the vertebral bodies during the automatic segmentation
step. To overcome this, we will incorporate an option to manually adjust this border in the workspace
of the RPA where the physician reviews the treatment plan.
3.3.1.4 Optimization of the dose distribution
Figure 4 shows a comparison of the maximum dose for each patient with automatic beam-weight
optimization versus without optimization. The maximum dose was significantly lower using
automatically optimized beam weights, with a median change of −1.9% (P < 0.001, range −10.0% to
+0.4%). In addition, there was a small yet statistically significant increase in the coverage of the treated
volume. The median percentage of the volume covered by 95% of the prescription increased by 0.6% (P
< .001, range: −2.8% to +2.8%).

16

Figure 4. Maximum dose was reduced using automatic beam-weight optimization. The maximum dose
(hottest 1 cc) is shown for each patient (n = 149) as a percentage of the prescription dose for optimized
versus equal beam weights (nonoptimized). The dotted line represents no change in the maximum
dose, and all points below this line showed a reduction in the maximum dose. The reduction was
especially large for patients who had very high maximum doses using equal beam weights.
The use of automatic beam-weight optimization was especially beneficial for patients with high
maximum dose (≥ 107% of the prescription dose) without optimization. These patients’ plans
experienced a larger median change in maximum dose (−3.5%). Furthermore, the percentage of
patients with high maximum doses was reduced from 44% without optimization to 3% with
optimization. Figure 5 shows the dose distribution of one axial slice from one patient whose very high
maximum dose was greatly reduced using optimized beam weights.
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Figure 5. Patient plans with high maximum doses experience a substantial reduction in the maximum
dose with automatic beam-weight optimization. The resulting dose distribution for an (A) automatically
planned four-field box with equal beam weights (nonoptimized) and (B) automatically optimized beam
weights. The maximum dose was reduced from 117% to 107% of the prescription dose for this patient.
3.3.1.5 Running time of the RPA system
Once the planning CT scan and plan order were imported, the fully integrated RPA created a plan in
Eclipse ready for physician review in a median of 11.0 minutes (range, 8.2 to 13.6 minutes).
3.3.1.6 Running the RPA remotely in patients at two South African hospitals
Of the 14 treatment plans created on the planning CT scans of patients from the partner hospitals
in South Africa, 100% were approved for treatment by the physician (10 plans from Tygerberg Hospital
and four from Groote Schuur Hospital).
3.3.2 Clinical Deployment at MD Anderson
Since the clinical version of the RPA was deployed at MD Anderson, it has been used in the planning
of 24 patients with cervical cancer. The location of the marked isocenter was not adjusted for 20
patients and was adjusted less than 1 mm for four patients. The physicians edited the automatically
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created treatment fields on the basis of their contours of the target and normal tissues. When
comparing the fields before and after physician edits, the median mean surface distance was 3.5 mm
(SD, 2.4 mm; range, 0.0 to 10.4 mm) and the median Hausdorff distance was 13.9 (SD, 9.1; range, 0.0 to
42.0) mm.

3.4 Discussion
In this work, we validated the RPA’s algorithms with physician review of a large cohort of patients
and performed remote testing of the fully integrated RPA. This work represents a critical step before
implementation of the fully automated system in the clinic. To our knowledge, this is the first work
toward automated treatment planning for radiation therapy of cervical cancer.
Before this study, the algorithms for defining the beam apertures were honed over several testing
iterations on more than 250 patient CT scans with feedback from physicians at MD Anderson and
Tygerberg Hospital and on the basis of the clinical edits made by physicians using the MD Andersondeployed version of the RPA. The final algorithm, validated in this study, was a consensus of the
radiation oncologists for patients whose disease extent was limited to the upper two-thirds of the
vagina and with only pelvic lymph node involvement. In the future, we can extend this work for
patients with more advanced disease (eg, involvement of the distal vagina or paraaortic nodes) by
including variations on the beam-aperture definitions. Within the RPA workflow, the rules by which the
beam apertures are defined can be adjusted for a range of disease stages, as long as these rules are
based on automatically segmented bony anatomy.
In addition to extensive retrospective testing at MD Anderson, we conducted a successful
retrospective test of remote, fully automatic treatment planning at two clinics in South Africa. Moving
forward, we will prepare for clinical deployment and testing, beginning with our two partner clinics in
South Africa. We will monitor the prospective use of the RPA and evaluate its effect on clinical
workflow, including the time staff spend planning and the time from CT simulation to first treatment.
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During this testing, we expect to address challenges on the basis of differences in clinical workflow and
software and hardware platforms. Ultimately, our goal is to deploy in clinics with fewer resources,
which will likely introduce new challenges in terms of staffing, workflow, and equipment. We also are
evaluating options to make this tool accessible to low-resource clinics, considering that there may be
limited financial resources available. In addition, we are developing automated treatment planning for
head-and-neck cancer radiation therapy [41] and postmastectomy chest-wall radiation therapy [37].
The treatment technique planned by the RPA is recommended for cervical cancer in low-resource
clinics, according to the International Atomic Energy Agency and ASCO [10], [11]. Although treatment
apertures on the basis of soft-tissue contours would be preferable for curative treatments, the bony
anatomy approach is used as an alternative in low-resource settings where there is a lack of staff to
complete the manual contouring necessary for more conformal treatments. With plans created by the
RPA, the physician can use the automatically created documentation to review the dose distribution
and evaluate the plan’s coverage, even without having contoured the soft-tissue disease.
Given the prevalence of cervical cancer, the fully automatic treatment planning offered by the RPA
could help alleviate staff shortages in low-resource clinics. In addition, by reducing the back-and-forth
handoffs between planners and physicians needed to manually plan a treatment, the automated
system could prepare a plan more quickly, presenting a plan for review shortly after the CT scan is
acquired. We envision the RPA facilitating same-day treatments, where a patient never has to leave the
clinic between CT scan and her first treatment. In contrast, for patients with gynecologic pelvic disease
in our clinical practice, the median planning time is 21 hours (interquartile range, 7 to 47 hours) from
CT simulation to when the plan is ready for physician review, including handoffs and time when the
plan is not being actively worked on (unpublished data). Furthermore, handoffs between staff have
been identified as a weakness in radiotherapy safety, and any reduction in the number of handoffs may
result in an improvement in the safety of radiation therapy [42], [43].
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The results of this study indicate that fully automatic treatment planning for cervical cancer is
achievable. More prospective studies are necessary and are ongoing in the United States and planned
with our international partner clinics. By reducing the work required by trained staff, the RPA could
ease the burden of creating patient-specific treatment plans in resource-constrained clinics. As a result,
using the RPA to automatically plan treatments could help reduce some of the barriers to establishing
radiation therapy programs.

Note: A statement of appropriate use of the automated planning tool for cervical cancer can be found
in Appendix A.
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Chapter 4 : Automated Treatment Planning for Radiotherapy of Postmastectomy
Breast Cancer

4.1 Introduction
Breast cancer is the most common cancer in women worldwide, including many low- and middleincome countries (LMICs) [1]. Generally, breast cancer is diagnosed at more advanced stages in LMICs
compared with more developed countries [3]. For breast cancer with four or more positive lymph
nodes, the standard of care is postmastectomy radiotherapy (PMRT) to the chest wall and ipsilateral
lymph nodes, which reduces the risk of local recurrence and improves survival [12]–[14]. There are also
increasing indications to deliver PMRT to patients with one to three positive lymph nodes or those with
high-risk node negative disease, as radiation in such situations is associated with improvement in
disease-free survival [15]. Planning PMRT treatments can be difficult and time-consuming, as it involves
using a complex combination of matched fields and various techniques to reduce the dose to organs at
risk (OARs) and improve the homogeneity of dose to the targets. Planning such treatments is further
complicated by the lack of access to technologies that facilitate deep-inspiration breath-hold
techniques that reduce the dose to the heart, which is often the case in resource-constrained clinics in
LMICs. These countries also have insufficient access to radiotherapy [23] in part because of a sizable
shortage in the trained staff needed to plan and deliver radiation treatment [24]. Treatment planning
constitutes a substantial amount of radiotherapy staff workload, and that workload could be reduced
by increased automation.
To date, most work on automating treatment planning for breast cancer has focused on a
tangential field-only treatment technique or on specific steps in treatment planning, such as the
inverse-planning of tangential intensity-modulated radiotherapy [30]–[34]. Many of these techniques
are effective and have improved the efficiency of treatment planning. Expanding from these efforts, we
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have developed a tool that automates the entire planning process for PMRT, which is necessary for
treating more advanced breast cancers. The PMRT technique differs from the previously automated
tangential field-only technique in that it includes a supraclavicular (SCV) field that is matched to
tangential fields via a non-divergent border at the match line. Another unique feature of our current
automation technique is that previous automation techniques require a particular placement of
external fiducial markers, which is not standardized among clinics; the techniques and materials used
for placing these markers vary greatly. Our goal in the present study was to develop an automated
technique for planning PMRT that can be widely used at multiple institutions around the world. Thus,
we designed a tool that does not require placement of external fiducial markers to determine the
borders of the treatment fields.
Herein we describe the automated treatment planning tool we developed, including the techniques
used for automation and the results of a planning study for patients with breast cancer who underwent
PMRT. We developed this automated planning tool in a collaboration between institutions in the
United States and South Africa, and it is intended for use in resource-constrained settings for
radiotherapy for locally advanced breast cancer after mastectomy.

4.2 Materials and Methods
4.2.1 Overview of the automated planning tool
The automated planning tool tested in this work designs PMRT treatments using a monoisocentric
tangential and SCV field technique. To reduce the dose to OARs and improve dose homogeneity in the
targets, the algorithms in this tool optimize the use of mixed high- and low-energy photon beams and,
for the tangential fields, the use of field-in-field (FIF) segments. The automated planning tool was
developed assuming the radiation treatments would be planned on a free-breathing computed
tomography (CT) scans of patients in the head-first, supine position owing to resource limitations. The
only external fiducial markers required are those indicating the position of the marked isocenter (i.e.,
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wires are not necessary for determining the beam geometry). The external fiducial markers indicating
the marked isocenter are automatically detected as described previously [44]. The initial version of this
tool was developed for left-sided treatments only. Given the additional complexity of left-sided
treatments because of the heart’s proximity to the targets in these treatments, translating this
approach to right-sided treatments should be easier than translating it in the opposite direction.
Patient treatments were prescribed for a hypofractionated regimen of 40.05 Gy delivered in 15
fractions [45].
The techniques for PMRT planning automation used algorithms developed in-house that were
integrated with the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA, USA) via
its application programming interface. This PMRT planning tool is part of a suite of automated planning
tools called the Radiation Planning Assistant that is being developed to automate planning processes
for resource-constrained clinics [37] and currently includes treatment planning for radiotherapy of
cervical and head and neck cancers [41], [44]. The inputs required by the Radiation Planning Assistant
are a plan directive from the physician specifying the prescription and a CT scan for treatment planning.
Another input needed for automatically planning PMRT is the location of the inferior border of the
tangent. This additional user input is currently required because an automated technique for
identifying this border that is sufficiently reliable has yet to be found, largely because of substantial
variability between patients. Therefore, the user is required to identify the CT slice of the tangent fields’
inferior border before automated planning is initiated.
The overall workflow for our automation technique for PMRT is illustrated in Figure 6. After
automatic segmentation of the targets, OARs, and additional planning structures are two main
automated planning steps: (1) setting up the treatment beams and (2) optimizing the dose
distributions. These steps are described in detail below. Once automated planning is completed, the
user is presented with a composite treatment plan consisting of the tangential and SCV field plans,
calculated dose, and heart and ipsilateral (left) lung contours, all of which are created automatically.
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We also implemented a technique to automatically verify the quality of the treatment plan and
determine when it deviates from standard quality metrics to flag these deviations to the reviewer of
the plan.

Figure 6. Overview of the method for automated planning of postmastectomy radiotherapy. OARs,
organs at risk; BEV, beam’s eye view; ROIs, regions of interest.
4.2.1.1 Automation of segmentation
The first step in our planning process is to automatically segment various anatomic structures,
including the targets (chest wall and lymph nodes), several OARs (e.g., both lungs, heart, spinal canal),
and other structures useful in defining beam geometry (e.g., sternum, clavicle, trachea). Automated
segmentation was done by deforming multiple atlases of patient contours to the target patient and
combining the deformed contours by using fusion based on the Simultaneous Truth and Performance
Level Estimation [46], [47]. These atlases were created by our group and consisted of 11 patient CT
scans with contours. This multi-atlas segmentation approach has been successfully used for many other
anatomic sites [39]–[41].
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4.2.1.2 Automation of beam setup
Once automatic segmentation was complete, the next step was to determine the CT slice of the
isocenter, representing the match line between the tangential fields and the SCV field. This slice was
initially placed at the inferior aspect of the clavicular head. From there, the posterior, non-divergent
border of the tangential fields (the principal border of the tangents separating the chest wall from the
OARs) was determined by using support vector machine classification. This technique was adapted
from the work described by Zhao et al. [33] and assigned points within the contours to one of two
classes: target (chest wall) and avoidance (heart, lungs, and contralateral breast). These classified
points were used as inputs to the support vector machine to determine the optimal three-dimensional
plane separating the two classes. This plane represents the posterior border of the tangential fields and
can be used to derive the beam parameters for the medial and lateral tangential fields, including the
gantry angles, collimator angles, and jaw/multileaf collimator (MLC) positions defining the posterior
border. The collimator angle is set to zero, and the posterior border is defined using the MLC. The
anterior jaw is defined to provide 2 cm of flash from the projection of the body contour. The inferior
jaw is defined at the projection of the slice of the body contour at the inferior border (which was
previously defined manually).
The first step in defining the SCV beam parameters after automatic segmentation was to determine
the optimal medial border separating the targets (SCV lymph nodes) from the avoidance tissues
(trachea and spinal canal). Again, a support vector machine was used to find the optimal plane, and this
plane was used to define the gantry angle and medial jaw/MLC positions of the SCV field. Finally, the
superior jaw was determined based on the beam’s eye view (BEV) projection of the cricoid cartilage,
and the lateral jaw and MLC positions for humeral head blocking were determined based on the BEV
projection of the humeral head.
In some cases, the location of the match line (and isocenter in the superior-inferior direction)
had to be automatically adjusted based on the patient’s anatomy and beam geometry. If the tangential
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field length exceeded the machine capabilities (>20 cm for a Varian C-arm linear accelerator) or the part
of the SCV field inferior to the humeral head was insufficient (<2 cm), the location of the match line was
automatically adjusted toward the inferior direction, and planning continued. In some cases with
excessive lung exposure in the SCV field (>4 cm based on the projection of the lung in the BEV), the
match line was moved more toward the superior direction. In the latter case, two plans were created:
the original plan with the match line at the inferior aspect of the clavicular head and an alternative plan
with a more superior match line to reduce the amount of lung in the SCV field. The rationale for
creating two plans was that several clinical factors contributed to the decision to move the match line,
including the location of the level III axillary nodes and the possibility of the tangential fields
intersecting part of the patient’s arm. If upon reviewing the original plan the physician decides that
moving the match line in the superior direction is advantageous, he or she can review the alternative
match line plan. The alternative match line plans were created while still considering the constraints of
maximum tangential field length and proximity of the match line to the humeral head. Figure 7
illustrates an example of the resulting SCV field BEV for the original and alternative match line plans for
one of the test patients.

Figure 7. Beam’s eye view of supraclavicular fields for the original match line plan (left) and alternative
match line plan (right) for the same patient. The contour of the level III axillary nodes are shown
projected in orange.
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4.2.1.3 Automation of dose optimization
Once the parameters for the open beams were determined, the three beams (medial and lateral
tangents and SCV) were automatically generated in the treatment planning system and calculated for
both 6- and 18-MV photons. Next, the dose per beam was exported and used as inputs for optimizing
the dose distribution to reduce the maximum dose in the plan and the doses to OARs while maintaining
target coverage. First, a normalization volume was created for each plan (tangential and SCV). These
normalization volumes were derived from the automatic segmentations of the target structures (chest
wall for the tangential plan and SCV and level III axillary lymph nodes for the SCV plan) that fell within
the limits of the treatment fields. The normalization volumes were used to ensure that coverage was
maintained throughout the optimization such that 95% of the normalization volume received 95% of
the prescribed dose.
In the optimization of the dose distribution, the relative weights of the high- and low-energy beams
were determined first for the open fields by using a brute-force search strategy. Next, for the tangential
fields, one or two FIF segments were created iteratively by blocking the dose cloud of the hot spots
within each BEV, mimicking a forward-planning methodology. The dose of the hot spot was determined
adaptively based on the current maximum dose in the optimization and the relative size of the dose
cloud. The beam energy of each FIF segment and relative weighting were also determined by using a
brute-force search strategy. The final resulting plans could have at most two SCV fields (high- and lowenergy fields, no FIF segments) and four tangential field segments per beam angle (high- and lowenergy open fields, two FIF segments). Combining the FIF segments with the open fields would result in
a maximum of six treatment beams (two SCVs, two medial tangents, and two lateral tangents).
4.2.2 Evaluation of automated treatment planning
The performance of the automated planning tool was evaluated by using scans from a sample of 10
patients who underwent left-sided mastectomy and a free-breathing CT scan for radiotherapy planning
at a partner hospital in South Africa. These CT scans were acquired with the patient in the head-first,
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supine position on a breast board with both arms raised over the head. All patients had external fiducial
markers indicating their marked isocenters. Some patients had additional wires placed for treatment
planning, although the wires were not used in this study. These patients’ CT scans were not used during
algorithm development or preliminary testing of the automatic planning tool. All patient data used in
this study were handled in accordance with an approved institutional protocol.
4.2.2.1 Validation of automatic segmentation
Although our automated techniques for PMRT planning make use of several automatically
segmented structures for creating treatment plans, only the heart and ipsilateral (left) lung are
presented with the plan. Therefore, the accuracy of segmentation of these contours was validated by
comparing the automatically generated contours with physician-approved, manually edited contours.
The physician-approved contours were created by using our automatic segmentation tool and then
edited manually and reviewed and approved by a radiation oncologist (S.F.S.) with expertise in
treatment of breast cancer. The contours were created according to the guidelines provided in the
Breast Cancer Atlas for Radiation Therapy Planning from the Radiation Therapy Oncology Group [48].
The contours were compared geometrically by using the Dice similarity coefficient, mean surface
distance, and Hausdorff distance and dosimetrically by using differences in dose metrics for each set of
contours from the automatically planned treatments.
4.2.2.2 Assessment of the automatically created treatment plans
Once the automatically created plans were ready in the treatment planning system, they were
reviewed for acceptability for treatment by two radiation oncologists with expertise in the treatment of
breast cancer (D.A. and T.T.) at Groote Schuur Hospital (Cape Town, South Africa). The plans were rated
on a three-tiered scale: use plan as is, use plan with minor changes, and plan requires major changes.
The specific changes requested for each plan were recorded. If a physician requested to see the
alternative match line plan for a patient, that plan was shown to the physician (if it had been created),
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and the physician selected the preferred plan. The physicians’ final plan ratings were reported for their
selected preferred plans.
The selected plans were also assessed quantitatively for compliance with dose objectives for target
coverage, OARs, and maximum plan dose. These dose objectives were evaluated by using the physicianapproved, manually edited contours. Coverage of the following target structures was assessed: the
chest wall, SCV lymph nodes, and level III axillary lymph nodes. The preferred dose objectives and
acceptable dose limits used for evaluation of the targets and OARs are presented in Table 1. These
objectives were determined according to several sources, including recommendations from The Royal
College of Radiologists [45], objectives from the Alliance A221505 clinical trial of hypofractionated
PMRT (unpublished protocol) [49], and clinical constraints from collaborating institutions. Maximum
doses were assessed separately for tangential and SCV field plans (preferred maximum dose <112% of
the prescription) as well as for the composite plan (preferred maximum dose <116% of the
prescription).

Table 1. Hypofractionated PMRT dose objectives for target coverage and organs-at-risk
Structure

Dose metric

Preferred objective

Acceptable limit

Targets

Volume >95% Rx

>95%

n/a

Targets

Volume >90% Rx

n/a

>90%

Mean dose

<4 Gy

<6 Gy

Volume >25 Gy

<7%

<10%

Volume >17 Gy

<35%

<40%

Heart

Ipsilateral lung

Rx: prescription; n/a: not applicable.
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4.2.3. Automated verification of PMRT plan quality
Preliminary testing of automated PMRT planning techniques demonstrated that plans were most
commonly rejected because of their dosimetric properties rather than the geometric design of the
beam setup. As a result, automated verification of the dose distribution was integrated into the
automated PMRT planning tool to alert the plan reviewer to these potential dosimetric deviations, with
alert thresholds set based on published dose objectives or clinic-specific objectives. These thresholds
included maximum plan doses and doses to OARs. Additional verifications included those of the
amount of lung projected in the BEV of the SCV and beam properties, such as the SCV gantry angle
(Table 2). The ability of these verification tests to detect potential deviations in the quality of the
automatically planned treatments was evaluated for the 10 patient CT scans evaluated in this study.

Table 2. Thresholds for automated verification tests of automated PMRT plan quality
Test object

Test metric

Threshold

Maximum dose (composite)

Point dose

>116% of prescription

Maximum dose (tangential plan)

Point dose

>112% of prescription

Maximum dose (SCV plan)

Point dose

>112% of prescription

Heart dose

Mean dose

<4 Gy

Volume >25 Gy

<7%

Volume >17 Gy

<30%

Lung in SCV field

Projection height

<4 cm

SCV gantry angle

Angle off vertical

>15°

Ipsilateral lung dose
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4.3 Results
4.3.1 Validation of automatic segmentation
The results of the geometric comparison of the automatically generated and physician-approved
contours of the heart and ipsilateral lung are shown in Figure 8. The Dice similarity coefficient values
were all at least 0.85 for the heart and 0.93 for the ipsilateral lung, indicating very good agreement. We
also observed good agreement of the mean surface distance, with all values less than 0.5 cm for all
contours. The greatest differences between the automatically generated and physician-approved
contours, as indicated by the larger Hausdorff distances, occurred when one contour included more
slices in the superior or inferior direction than the other.
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Figure 8. Comparison of the automatically generated and physician-approved contours of the heart and
ipsilateral lung. The top row shows the following results of the geometric comparisons: Dice similarity
coefficient (DSC; left), mean surface distance (MSD; center), and Hausdorff distance (HD; right). The
bottom row shows the following results of the dosimetric comparisons: mean OAR dose (left) and dosevolume histogram metric (right). The absolute difference in metrics was the results for the physicianapproved contour minus that for the automatically generated contour for the same plan.
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The differences in the dose metrics when evaluated on the physician-approved contours compared
with the automatically generated contours of the heart and ipsilateral lung are also shown in Figure 8.
The differences were all small, resulting in less than a 1 Gy difference in mean dose and less than a 2%
difference in volume for the dose-volume histogram metrics. Although the dose to the physicianapproved contours did trend higher than the automatically generated contours, it did not affect
whether a plan met the dose objectives for planning. This demonstrates that using the doses to the
automatically generated contours is appropriate when reporting plan quality to the user. (Note: the
doses reported in the sections below are those to the manually edited contours.)
4.3.2 Assessment of the automatically created treatment plans
Upon physician review of the final 10 automatically planned treatments, the physicians rated all
plans either acceptable as is (50%) or with only minor changes (50%). Of these plans, four were the
alternative plans, in which the physicians preferred that the match line be placed more superior to the
original match line. For the 10 original plans, physicians requested to see an alternative match line plan
for five patients. One of these patients was constrained by the tangential field length limit (>20 cm), so
alternative plans were presented for the remaining four, all of which were preferred by the physicians.
Figure 9 shows an example of the dose distributions for a representative plan rated acceptable as is.
Physicians requested a total of seven changes for the five plans: adding a heart block to reduce the
heart dose in two patients, reducing the maximum dose in the tangential plan for one patient with a
large separation, and reducing the depth of nodal coverage to reduce the maximum dose in the SCV
plan, reducing the lung dose, adjusting the superior border of the SCV field, and adjusting the SCV angle
in one patient each.
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Figure 9. The resulting dose distribution for a test patient for whom the PMRT plan was rated use as is.
The dose is shown on three different axial slices of the CT scan: in the supraclavicular field (left), in the
superior half of the tangential fields (middle), and in the inferior half of the tangential fields (right).
The resulting dose metrics for the heart and ipsilateral lung, coverage of the targets, and maximum
doses are shown in Figure 10. Ninety percent of the plans met the acceptable objective for the heart,
with 60% meeting preferred objectives, and all of the plans met the preferred objectives for the
ipsilateral lung. Regarding target coverage, all of the plans met the preferred objective, in which 95% of
the volume was covered by 95% of the prescribed dose. Eighty percent of the plans met the preferred
objective for the maximum dose (<116% of the prescribed dose). The two patients’ plans that exceeded
this value had maximum doses less than 118% of the prescription dose that were caused by large chest
wall separation and deep lymph node targets. The locations of the maximum doses were checked to
ensure that they did not fall within the brachial plexus.
On average, we found that creation of one treatment plan took 38 min (range 28-52 min). For plans
for which an alternative match line plan was automatically created based on the amount of lung in the
SCV BEV, an average of 24 min (range 17-28 min) was added to the planning time. On average, the
majority of the time went toward setting up the beams (19 min), contouring (11 min), and dose
optimization (7 min). The automated planning tool tested in this system was implemented on a
standalone workstation. In the future, the system that will be deployed for clinical implementation will
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consist of a network of servers facilitating parallel processes, a distributed calculation framework, and
further improvements in computational speed.

Figure 10. The final dose metrics for the 10 automatically planned treatments. The dose-volume
histogram (DVH) metrics (top left), mean dose delivered to the heart and ipsilateral lung (top right),
coverage of targets by 95% or the prescription dose (bottom left), and maximum doses for the
tangential and SCV plans and for a composite of the two plans (bottom right) are shown. OARs, organs
at risk; SCV, supraclavicular; Ax3, level III axillary; Rx, prescription.
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4.3.3 Automated verification of PMRT plan quality
In their evaluation of the 10 treatment plans, physicians requested a total of seven changes
(described above) plus five requests to review alternative match line plans. Of these 12 requests, 11
(92%) were detected by the automatic plan quality verification tests. The only requested change not
detected was adjustment of the SCV field’s superior border. The tests detected four additional potential
deviations that the physicians did not request to be changed: two plans with slightly high heart doses,
one plan with a slightly high ipsilateral lung dose, and one plan with a slightly large amount of lung in
the SCV field. All four of these potential deviations were very close to the thresholds set for each test.

4.4 Discussion
In this work, we demonstrated the clinical viability of our automated planning tool for radiotherapy
for locally advanced breast cancer after mastectomy. We developed this tool with the goal of reducing
the workload on the limited radiotherapy staff of resource-constrained clinics, such as those in LMICs
[24]. Such automated tools have the potential to reduce staff workloads and improve the reliability of
treatment planning [50]. Investigators have shown that clinical implementation of automated planning
for tangential breast irradiation can improve the efficiency and quality of treatment planning, even
facilitating same-day treatments [30], [51]. We would expect an even greater gain in efficiency for
automation of the complex PMRT necessary for advanced breast cancers, which are more common in
LMICs owing to late-stage diagnosis. Some have also suggested that reducing the effort spent in
treatment planning through automation could reduce the cost of radiotherapy programs [25].
Automation of PMRT planning is a major step toward improving treatment planning efficiency,
especially given that breast cancer is one of the most common cancers in LMICs.
To our knowledge, this is the first automated treatment planning tool designed for PMRT, which
uses tangential fields to irradiate the chest wall matched with an oblique en face beam to irradiate the
SCV lymph nodes. Although some clinics may also include the internal mammary chain (IMC) lymph
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nodes in such treatment, this remains an area of controversy [17]. Treatment of the IMC increases the
dose delivered to the heart and the risk of heart disease [16]. In the context of patients undergoing
free-breathing treatments because of resource limitations in LMICs, the heart doses and risk of heart
disease are even higher. For this reason, clinics may only treat the IMC if these nodes are suspected of
being involved. Therefore, we designed our automated planning tool for a technique that irradiates the
chest wall and SCV and level III axillary lymph nodes, and not the IMC lymph nodes.
Without using external markers to set up the beams, the automation algorithms determined the
appropriate beam angles for the tangential fields in this test cohort. However, not using markers means
that one manual input is required for treatment planning: the location of the inferior border of the
tangential fields. In the user interface of our automated planning tool, this border is conveniently
selected in the same workspace in which the CT scan is approved for automated planning, which should
add negligible effort and time to the entire planning process. Also, clinicians may follow their typical
process for marking the inferior border, such as placement of a wire, to facilitate their selection of this
location. The patient CT scans we tested here as well as those used previously in the development of
this automated planning tool came from several different institutions. As a result, a variety of
approaches for placing markers and wires were used for these patients, which did not seem to
influence the performance of our algorithms in setting up the beams.
We also integrated a method into our automated planning tool to automatically alert reviewers of
the PMRT plan to any potential discrepancies in plan quality, which mainly resulted from the plan’s
dose distribution. Given the proximity of the targets to sensitive normal tissues and the variations in
patient anatomy, balancing normal tissue sparing and full target coverage is sometimes a challenge in
radiotherapy for breast cancer. We designed our automated treatment planning tool to create plans
with full coverage of the target volumes. Therefore, this automatic verification may be useful in alerting
the plan reviewer to potential discrepancies in plan quality, such as high heart dose, which may call for
adjustment of the plan depending on the acceptable clinical compromises for that particular patient
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and plan. The alerts generated by the automatic plan quality verification tests could help expedite
adjustment of treatment plans if necessary and improve the safety of automated treatment planning by
automatically alerting the plan reviewer to potential issues with the plan.
The current version of this automated planning tool for PMRT designs radiation treatments based
on specific clinical practices that may vary by institution, including patient positioning (supine, both
arms up), the use of free-breathing scans, the location of the match line or superior border of the SCV
field, and a hypofractionated treatment regimen. However, the automation techniques presented
herein can be easily adapted to comply with variations in this clinical practice. Some variations in
practice may require greater adaptations in the automation technique, but are still feasible. One
example is the use of a single-energy photon beam, which is common in many clinics, rather than a mix
of high- and low-energy beams. With adaptation, automation of PMRT with a single-energy photon
beam is very likely possible, although the dose distributions for many patients would be expected to be
hotter than those with mixed-energy photon beams. Another possible adaptation is using tangential
and SCV fields for the treatment of intact breast and at-risk nodes. By changing the automatic
segmentation to create the breast contour to use as the target for the tangents rather than the chest
wall, the automation techniques would function the same as those used for planning PMRT. Before
clinical implementation, all of these adaptations would need to be tested thoroughly.
In the evaluation described herein, we retrospectively planned PMRT treatments for a small cohort
of patients with locally advanced breast cancer after mastectomy that required only minor changes or
were acceptable for treatment as is. We also found that the automatic segmentation of the heart and
ipsilateral lung was sufficiently accurate for presentation to the end user. Moving forward, we will
subject this automated planning tool to prospective testing with our collaborating institutions before
clinical implementation. In this prospective testing, we will compare automatically generated PMRT
plans head-to-head with the corresponding manually created treatment plans.

39

Key considerations for clinical deployment of this automated treatment planning tool is ensuring
that patient selection and setup are appropriate for the treatment technique planned by this
automated tool. Thorough training will be necessary to ensure safe use and help users understand the
specifications of this system. During clinical implementation, we will collect data on planning times to
quantify improvements in efficiency when using this automated planning tool.

4.5 Conclusion
We developed and tested an automated planning tool for PMRT and demonstrated its viability for
implementation in resource-constrained clinics in LMICs. This tool has the potential to improve
efficiency in planning these complex treatments for breast cancer.

Note: A statement of appropriate use of the automated planning tool for cervical cancer can be found
in Appendix B.
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Chapter 5 : Assessment of Risk in Automated Treatment Planning
This chapter is based upon the following accepted article:
Kisling K, Johnson JL, Simonds H, Zhang L, Jhingran A, Beadle BM, Burger H, du Toi M, Joubert N, Makufa
R, Shaw W, Trauernicht C, Balter P, Howell R, Schmeler K, Court L. A Risk Assessment of Automated
Treatment Planning and Recommendations for Clinical Deployment. Med Phys.

5.1 Introduction
Automation has the potential to improve the consistency and efficiency of radiation treatment
planning. Additionally, the automation of treatment planning promises to improve safety by preventing
human errors and reducing handoffs between medical staff members, both of which have been shown
to be weaknesses in radiotherapy safety [42], [52], [53]. While it is generally assumed that automation
leads to elimination of the risks associated with human error, it can introduce new or different types of
error that are not part of the routine, manual treatment planning process. For example, automated
processes may introduce new or added risks from the lack of active participation by a human user who
could catch errors that may go undetected by computer algorithms.
As with any other new technology to be implemented into clinical workflow, it is vital to assess the
risk introduced by automated treatment planning in each step of the workflow. Furthermore, Task
Group 100 (TG-100) of the American Association of Physicists in Medicine (AAPM) recommends that all
new devices undergo a systematic risk analysis [53]. Failure mode and effects analysis (FMEA) is an
established technique for methodically and prospectively identifying the risks involved in a process. This
method has been used by several other groups to assess the risks of various processes in radiation
oncology practice [43], [54]–[57].
Our group recently developed a fully automatic treatment planning tool, the Radiation Planning
Assistant (RPA) [37], [44]. In addition to developing algorithms to automate treatment planning, we
also implemented a quality assurance (QA) program specific to the RPA in order to enhance the safety
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of automated planning. In the present work, we used FMEA to assess the risk of various failure modes
in automated planning for cervical cancer radiotherapy with the RPA. We then assessed the impact of
the specialized QA program on the identified risks.

5.2 Materials and Methods
5.2.1 Description of the RPA
The workflow of automated planning with the RPA was previously described by Court et al [37].
Currently, the RPA is being implemented as a remote system with which the user interacts via a web
interface. A locally installed system is also possible. The input to the RPA is a plan directive from the
physician with patient information, including the treatment site and prescription, and the planning
computed tomography (CT) images of the patient in the treatment position. In the RPA’s user interface,
qualified staff can enter, review, and approve the plan directive and planning CT. Once these are
approved, the RPA automatically begins planning.
The RPA is being developed for all treatment sites, starting with cancers of the uterine cervix, head
and neck, and breast. Here, we focused on RPA treatment planning for cervical cancer using a 4-field
box technique with beam apertures based on bony anatomy. The algorithms and validation results of
the RPA for cervical cancer have been previously described [44]. Briefly, the RPA uses in-housedeveloped algorithms that are integrated with the Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, CA) via Eclipse’s application programming interface. The marked isocenter is
automatically localized according to the positions of 3-point external fiducial markers, and the body
contour is automatically segmented. Next, the pelvic bony anatomy is automatically segmented with an
auto-segmentation tool using deformable registration of multiple atlases [46]. The pelvic bony anatomy
is projected into each beam’s-eye view, and the beam apertures are designed on the basis of
anatomical landmarks identified on the projections of the bony anatomy. The treatment beam
parameters are then automatically set in the treatment planning system, and the dose is calculated
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using the Analytical Anisotropic Algorithm. The relative beam weights are optimized to achieve a
homogeneous dose distribution within the treated volume.
After planning is complete, the RPA presents the plan as a PDF document for a physician to review.
If the physician approves the plan, DICOM-format treatment plan files are transferred to the user. The
expectation is that users will import the files into their own treatment planning systems for review
before treatment and will perform their standard pretreatment QA.
5.2.2 FMEA of Automated Planning
For the FMEA, a team of subject-matter experts (3 medical physicists and 1 radiation oncologist)
first enumerated the steps in the RPA automated treatment planning workflow for patients with
cervical cancer, from CT simulation to plan approval by the physician. Then, for each process step, the
group of 3 physicists identified potential failure modes and possible causes of each failure mode. The
process map, failure modes, and scoring were determined assuming a generic clinic that follows the
practices outlined in the American College of Radiology accreditation requirements, including physics
plan review [58]. Prior to scoring, the process map and potential failure modes and causes were
reviewed by 6 medical physicists at 4 centers in South Africa and Botswana that are prospective users
of the RPA. These physicists assessed the applicability of the proposed treatment planning workflow
and failure modes to their local clinical practice to identify any substantial discrepancies, and none
were found.
Next, the original team of 3 physicists scored the likelihood of occurrence (O), the severity (S), and
the likelihood of going undetected (D) for each potential cause of each potential failure mode using a
10-point scoring system. For scoring O and D, we used the values recommended in Table II of the TG100 report [53]. For scoring S, we used the system recommended by Faught, which augments the
original definitions in the TG-100 report with quantitative descriptions of the severity [59]. This system
is reproduced here in Table 3. The value for each O, S, and D score was the consensus value as
determined by the group. We chose to focus on scoring the causes of failure modes individually in
43

order to better design the QA program to mitigate the variable risks attributable to different causes of a
potential failure mode.

Table 3. The system used for scoring the severity of a potential failure mode, reproduced from Faught
[59].

Severity
Score (S)

Qualitative Definition

Quantitative
Definition

1

No effect

0.0%-2.9%

2

Inconvenience

3.0%-3.9%

3

4.0%-4.9%

4

Minor dosimetric error, suboptimal plan or treatment

5.0%-6.9%

5

Limited toxicity or tumor underdose. Wrong dose, dose
distribution, location, or volume

7.0%-8.9%

6
7

9.0%-9.9%
Recordable event. Potentially serious toxicity or tumor under
dose

8

10.0%-14.9%
15.0%-19.9%

9

Reportable event. Possible very serious toxicity or tumor
under dose. Very wrong dose, dose distribution, location, or
volume

20.0%-49.9%

10

Catastrophic

≥50.0%

A risk priority number (RPN) was calculated by multiplying the O, S, and D scores. For potential
failure modes with causes that were specifically related to the failure of an RPA algorithm, we were
able to determine the O score quantitatively on the basis of our retrospective testing of the RPA using
approximately 500 patient CT scans rather than making an estimate of the percent likelihood of
occurrence. For example, a specific algorithm failure that occurred twice during testing would receive
an O score of 6, representing an occurrence rate of less than 0.5%. If a potential failure mode never
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occurred, we estimated the likelihood of occurrence from our experience and knowledge of the
algorithms.
5.2.3 Description of the QA Program
To minimize opportunities for error, we implemented a QA program for the RPA that included 3
types of QA to detect errors in the automatically created treatment plans. We applied this QA program,
which is intended to supplement users’ standard QA processes, to all possible steps in the automated
planning process. This QA program was initially developed prior to the FMEA based on our experience
with the initial retrospective testing and development. The QA program was updated with additional
tests based on the results of this FMEA.
The first type of QA applied was an automatic, independent validation of the results of each step,
which is a similar concept to the independent dose verification used in radiotherapy. For example, we
use 2 independent methods to automatically detect the marked isocenter based on a 3-point external
fiducial setup. The primary method searches within a band around the body contour for the high
contrast external fiducials. The secondary method differs in that it searches for high contrast objects
that constitute a triangle topology. The result of the primary method is used in the treatment plan, and
its agreement with the results of the secondary method is verified. If the 2 methods do not agree, the
treatment plan is flagged for human review. Other examples of tasks that have 2 independent
algorithms are segmentation of the body contour and creation of the field apertures. We pushed the
treatment plans to Mobius3D (Mobius Medical Systems, Houston, TX) to perform the secondary dose
verification. We also automatically verified the patient’s orientation and anatomical site (e.g., head vs.
pelvis) using both the DICOM header information and a simple rigid registration to a full-body patient
CT scan.
The second type of QA was an automatic check of the result against expected values. The expected
values may be a range derived from the population of patient plans, such as for field size, or a single
value, such as the collimator angle always being equal to 0.
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Finally, the third type of QA was a series of specialized manual checks. One such manual check was
a set of specific questions in the user interfaces for approving the plan directive and planning CT. For
example, we asked the user to verify that the CT scan field of view was appropriate for the patient.
Another manual check was plan documentation that was automatically created and designed to guide
the appropriate staff, such as a physicist, through checking the treatment planning parameters.
5.2.4 Assessment of the Effect of the QA Program
We next assessed the effect of the QA program on the detectability of each failure mode and cause.
First, we determined which failure modes could be detected by any of the 3 types of QA described
above. For each type of QA, we estimated how effectively that type of QA could improve the
detectability of that failure mode and cause using a 3-tier scale: very effectively, moderately effectively,
or somewhat effectively. We used these ratings to adjust the D value (the likelihood of going
undetected) for each failure mode by reducing the percentage of undetected failures (from the
corresponding score values in Table II from TG-100). To facilitate the reduction in the D value, we
assigned residual percent undetected values of 20%, 50%, and 80% to the very, moderately, and
somewhat effective types of QA, respectively, based on the likely effectiveness as determined by group
consensus. These reduced values were then converted back to a D score on the 10-point scale from TG100. We then calculated the differences in the RPN of all potential failure modes with and without the
QA program.

5.3 Results
The RPA process, with its 4 major subprocesses (CT simulation, plan directive, RPA plan creation,
and plan approval) and 30 steps, is shown in Figure 11. Using FMEA, we identified 68 failure modes with
113 potential causes. The full results of the FMEA can be found in Appendix C. Of the 113 potential
causes, 79 (70%) were subject to at least 1 type of QA as part of our QA program (not including typical
clinical QA practices). Without the QA program, the average RPN was 91, and the maximum RPN was
46

504. With the QA program, these values were reduced to 68 and 315, respectively. The distribution of
the RPNs with and without the QA program for all potential failure modes and causes is shown in Figure
12, where the overall shift to lower RPN values is apparent. Since the QA program only affected the
detectability of failures, we compared the change in the distribution of the D scores with and without
the QA program (Figure 13). The median D score without the QA program was 5.0 and was reduced to
3.0 with the QA program.
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Figure 11. Depiction of the subprocesses and steps involved in automatically planning a 4-field box
radiotherapy treatment for cervical cancer with the Radiation Planning Assistant (RPA). Subprocesses 1
and 2 (CT simulation and plan directive) involve many manual steps from which errors could propagate
downstream. Subprocess 3 (RPA plan creation) is entirely automatic. Abbreviations: MLC, multileaf
collimator; TPS, treatment planning system.
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Figure 12. Histogram of the risk priority numbers (RPN) for all potential failure modes identified for
automatic planning of a cervical cancer treatment using the Radiation Planning Assistant (RPA) with
(blue) and without (red) the QA program.
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Figure 13. Histogram of the detectability score (D) for all potential failure modes identified for
automatic planning of a cervical cancer treatment using the Radiation Planning Assistant (RPA) with
(blue) and without (red) the QA program.
Scores for the top 10 potential failure modes and associated causes are shown in Table 4 and Table
5 for the RPA without the QA program and with the QA program, respectively. Without the QA
program, 3 of the top 10 failure modes were related to a failure to correctly identify the marked
isocenter based on the external fiducials. A failure in this step could have severe consequences if not
detected and is not unique to automated treatment planning. Incorrect definition of the isocenter was
also identified as a relatively high-risk failure mode in an FMEA of pretreatment steps for TomoTherapy
by Broggi et al [55]. The QA program of the RPA includes automatic verification of the isocenter and a
guided manual check of the isocenter identification in the plan documentation. With the QA program,
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only 1 of the top 10 failure modes involved identification of the isocenter. This failure mode was caused
by the presence of other external fiducials on the planning CT scan (e.g., wires), which could reduce the
effectiveness of the automatic verification QA process.

Table 4. The top 10 potential failure modes and their causes in automated planning with the Radiation
Planning Assistant (RPA) without the quality assurance (QA) program.

#

Major
process

Step

Potential failure
mode

Potential causes
of failure

O

S

D

RPN

1

RPA plan
creation

Isocenter
position

Incorrectly identified

Other external
fiducials

7

9

8

504

2

RPA plan
creation

Jaw positions

Inappropriate
position

Algorithm error

10

7

6

420

3

RPA plan
creation

MLC positions

Inappropriate
position

Algorithm error

10

7

6

420

4

Plan
approval

Physician plan
review

No comprehensive
review

Human error

3

10

10

300

5

RPA plan
creation

Isocenter
position

Incorrectly identified

Algorithm error

4

9

8

288

6

CT
simulation

Select CT
protocol and
execute

Field-of-view is too
small

Human error

5

8

7

280

7

CT
simulation

Select CT
protocol and
execute

Field-of-view is too
small

Patient is too
large

5

8

7

280

8

Plan
directive

Enter
prescription

Incorrect (not
changed from
default)

Human error

4

9

7

252

9

RPA plan
creation

Dose
distribution

Calculation point is
inappropriate

Located in high
or low CT
number

10

4

6

240

10

RPA plan
creation

Isocenter
position

Incorrectly identified

External fiducials
out of range of
scan

3

9

8

216

Abbreviations: O, occurrence score; S, severity score; D, detectability score; RPN, risk priority number;
MLC, multileaf collimator; CT, computed tomography.
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Table 5. The top 10 potential failure modes and their causes in automated planning with the Radiation
Planning Assistant (RPA) with the quality assurance (QA) program.

#

Major
process

Step

Potential failure
mode

Potential causes
of failure

O

S

D

RPN

1

RPA plan
creation

Isocenter
position

Incorrectly identified

Other external
fiducials

7

9

5

315

2

Plan
approval

Physician plan
review

No comprehensive
review

Human error

3

10

10

300

3

RPA plan
creation

Jaw positions

Inappropriate
position

Algorithm error

10

7

4

280

4

RPA plan
creation

MLC positions

Inappropriate
position

Algorithm error

10

7

4

280

5

Plan
directive

Enter
prescription

Incorrect (not
changed from
default)

Human error

4

9

7

252

6

CT
simulation

Select CT
protocol and
execute

Field-of-view is too
small

Human error

5

8

6

240

7

CT
simulation

Select CT
protocol and
execute

Field-of-view is too
small

Patient is too
large

5

8

6

240

8

Plan
directive

Questions
about patient
appropriateness

Completed
incorrectly

Human error

4

9

5

180

9

Plan
directive

Approve plan
directive

Approved by staff
without correct
rights

Shared
login/Incorrect
rights

4

9

5

180

10

CT
simulation

Position patient

Inappropriate
positioning

Human error

6

4

7

168

Abbreviations: O, occurrence score; S, severity score; D, detectability score; RPN, risk priority number;
MLC, multileaf collimator; CT, computed tomography.

Other important potential failure modes, with and without the QA program, were the definition of
the beam apertures (jaws and multileaf collimator). We implemented automatic QA verification to
detect gross errors in beam aperture definition. However, it remains vital that the physician review the
appropriateness of the beam apertures, regardless of whether the beam apertures are determined
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automatically by computer algorithms or drawn manually by a dosimetrist or resident. In fact, a
potential failure mode identified by both our FMEA and that of other groups was failure of the
physician review of plan quality [53], [56]. While physician review is standard clinical practice, and such
a failure is unlikely, it would be very difficult to detect and could have severe consequences if the plan
quality is inadequate. We have previously shown that nonspecialists are unlikely to reliably identify
these errors, even when presented with examples of correct beam apertures as a reference [37].
We specifically investigated the 15 higher-risk failure modes—those for which the RPN was greater
than or equal to 200. Of these, 13 (87%) were subject to at least 1 type of QA technique. The number of
these higher-risk failure modes was reduced from 15 to 7 when the QA program was implemented,
with an average reduction in RPN score of 93 points (range, 40-189). Physician review of the plan was 1
of the 2 higher-risk failure modes that could not be mitigated by a specialized QA technique (beyond
standard clinical practice).
The other top failure mode that was not subject to a specialized QA technique was an incorrectly
entered prescription in the plan directive workspace, specifically cases in which the physician intended
to change the prescription from the default or typical value. While such a scenario is unlikely, this
failure would be more difficult to catch later in a manual check, since the intended prescription would
not be the expected, typical value for that patient type. Automation does mitigate many potential
transcription errors (such as those that occur between the plan directive and the treatment planning
system). However, the initial entry into the system must be as the planning physician intends,
regardless of whether manual or automated treatment planning is used. In fact, incorrect prescription
has been identified as a potentially severe failure mode by other groups studying manual treatment
planning [55], [56].
We also investigated the 22 failure modes and associated causes with high severity scores (S ≥ 9).
Table 6 lists all failure modes and causes with S scores of 9 or higher, including their overall scores with
the specialized QA program. Here, we found that 14 (64%) failure modes were subject to at least 1 type
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of QA. On average, the RPN of the high-severity failure modes was reduced from 146 to 113 with the
QA program implemented. The maximum RPN for these was reduced from 504 to 315. Most of these
failure modes were unlikely to occur; 20 (91%) had O scores of 4 or less. With 1 exception, the highseverity potential failure modes that were not subject to any specialized QA test were caused by human
error, such as incorrectly entering the prescription in the plan directive.

Table 6. Potential automated treatment planning failure modes and associated causes with severity (S)
scores of 9 or higher. Scores shown are for the Radiation Planning Assistant (RPA) with the quality
assurance (QA) program implemented.

Major
process

Step

Potential failure
mode

Potential causes of
failure

O

S

D

RPN

CT
simulation

Enter patient
information

Incorrect name or ID
entered

Human error

1

10

9

90

Plan
directive

Enter patient
information

Incorrect name or ID
entered

Human error

2

10

1

20

RPA plan
creation

Prescription set

Does not match the
plan directive

Algorithm error

1

10

5

50

RPA plan
creation

Prescription set

Incorrect
normalization

Algorithm error

1

10

5

50

RPA plan
creation

Dose distribution

Calculation point not
at isocenter

Algorithm error

1

10

5

50

RPA plan
creation

Plan
documentation

Data corrupted

Algorithm error

3

10

4

120

Plan
approval

Physician plan
review

No comprehensive
review

Human error

3

10 10

300

Plan
approval

Data transfer
from RPA to local
TPS

Data corrupted

Network error

2

10

3

60

CT
simulation

Position patient

Incorrect orientation

Human error

3

9

2

54

CT
simulation

Position patient

Incorrect orientation

6

9

1

54

CT
simulation

Position patient

Incorrect orientation

4

9

2

72

Standard technique
varies from RPA
protocol
Intentional nonstandard technique

54

Plan
directive
Plan
directive

Questions about
patient
appropriateness
Questions about
patient
appropriateness

Completed
incorrectly

Human error

2

9

7

126

Completed
incorrectly

Human error

4

9

5

180

Incorrect (not
changed from
default)

Human error

4

9

7

252

Human error

3

9

6

162

Shared login/incorrect
rights

4

9

5

180

Plan
directive

Enter
prescription

Plan
directive

Enter
prescription

Plan
directive

Approve plan
order

RPA plan
creation

Isocenter
position

Incorrectly identified

Other external fiducials

7

9

5

315

RPA plan
creation

Isocenter
position

Incorrectly identified

Fiducials out of range
of CT

3

9

4

108

RPA plan
creation

Isocenter
position

Incorrectly identified

Algorithm error

4

9

4

144

RPA plan
creation

All 4 beams
created

Not created at the
isocenter

Algorithm error before
aperture generation

1

9

6

54

RPA plan
creation

All 4 beams
created

Not created at the
isocenter

Algorithm error after
aperture generation

1

9

2

18

RPA plan
creation

MLC positions

MLC missing from
plan

Algorithm error

1

9

2

18

Incorrect (changed
from default)
Approved by person
without correct
rights

Note: Potential failures in the “Plan directive” step “Questions about patient appropriateness” were
scored by considering 2 separate scenarios: (1) when the result does not affect the results of
automated planning, but still poses a risk (such as prior irradiation); and (2) when the result would
technically affect the result of automated planning (such as the presence of an artificial hip, which may
cause errors in contouring the bony anatomy).
Abbreviations: O, occurrence score; D, detectability score; RPN, risk priority number; CT, computed
tomography; TPS, treatment planning system; MLC, multileaf collimator.

5.4 Discussion
Following the recommendation of TG-100 to perform a risk analysis of new technologies to be
implemented in clinical practice, we assessed the risk of our recently developed automated treatment
planning tool, the RPA. To our knowledge, this is the first published work assessing the risk of
automated treatment planning using FMEA. Additionally, we determined the effect of the specialized
QA program on the RPA’s failure risk. This work has enabled us to systematically and prospectively
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identify the highest-risk steps involved in our automated treatment planning workflow and aided us in
developing a QA program specific to the RPA.
While the FMEA presented here is specific to the workflow of the RPA, the lessons gained can be
applied broadly to implementations of automated planning. The current analysis has shown us that
many of the highest-risk steps, both with and without the QA program (as shown in Table 4 and Table
5), are similar to what might be expected in a manual treatment planning process, including correct
identification of the marked isocenter, use of appropriate beam apertures, and use of the correct
prescription. However, while the resulting failures may be the same, the causes of these failures may
be different in automated planning, in which an algorithm, rather than a human planner, may fail to
perform adequately. We have found that many of the highest risk errors in our automated planning
workflow were caused by human error. Such errors in an automated plan can be readily detected by
the physicist or physician who reviews the plan, as in standard clinical practice. The results of this study
emphasize the importance of these plan reviews prior to patient treatment, regardless of whether the
plan was generated automatically or using standard manual techniques. In fact, with the advent of
automated treatment planning, we need to ensure that we do not develop an overreliance on
automation and forego the usual attention to detail in the manual review of treatment plans. In
general, automation can improve the safety and consistency of many steps of treatment planning,
especially for more objective tasks such as setting prescriptions and creating the beams at the correct
isocenter. However, for more subjective tasks, such as designing treatment beams or contouring, the
automation techniques and algorithms, like a human planner, have a certain level of skill, so their
results should always be scrutinized by qualified staff.
Using automated QA techniques for plan review has been proposed by several groups [60]–[63].
Here, we incorporated such checks for the consistency and reasonability of the treatment planning
parameters as part of our QA program. Additionally, we included automatic verification of more
subjective tasks, such as designing beam apertures. These automatic checks add additional risk
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mitigation without additional workload on staff, which is especially important for resource-constrained
settings. However, our QA program only addresses potential failure modes in treatment planning and
does not address failures that may occur as plans are transferred to the local treatment planning
system or record-and-verify system, although we have developed software to check the integrity of this
data transfer.
In addition, our study revealed that automation of treatment planning and QA does not completely
remove the risk of human error. For example, the effect of an incorrectly entered prescription is still a
high-risk point that can only be detected by a diligent human review. To address this, the third
component of our QA program, the specialized manual checks, was designed to draw the reviewer’s
attention to these important components of the treatment plan. However, there are still potential
failures that are not covered by any of our QA program, including the specialized manual checks. Many
of these potential failures could be caught by standard QA steps, such as the typical physics and
physician plan reviews which could detect if there was a discrepancy of the prescription or an
abnormality in the plan. To reinforce the importance of the manual checks as we clinically implement
automated planning, training of the users of the RPA will be vital to overcoming the residual higher-risk
failure modes. The results of this FMEA will inform the training by educating the users on what are the
highest-risk potential failure modes that should be included in their manual checks.
Our analysis of approximately 500 test cases was able to quantify some of the values for the
likelihood of occurrence of potential failure modes caused by algorithm error. However, most of the
failure modes we identified prospectively through the FMEA did not materialize in this testing.
Therefore, the O scores were estimated for these potential failure modes on the basis of the FMEA
team’s experience and knowledge of the RPA algorithms. In order to further quantify and improve the
reliability of the FMEA results, more extensive testing will be necessary in the course of pre- and early
implementation. Therefore, the results of this FMEA will be a living document that will be updated as
more testing occurs. This is similar to techniques that incorporate data from incident-learning systems
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to validate and improve upon FMEA findings. We intend to conduct regular reviews and, if necessary,
update the FMEA throughout the testing, clinical implementation, and use of the RPA. By continuing to
monitor the RPA’s performance, the occurrence of failures, and the ability of the QA program to detect
failures, we will collect quantitative data that will improve the validity of the FMEA.
Additionally, before implementing automated planning for other treatment sites or techniques
using the RPA, we will reassess the process map and failure modes. For example, in planning volumetric
modulated arc therapy for head and neck cancers, contouring is a vital step that has been identified by
other groups as a high-risk potential failure mode [43], [53], [55]. Therefore, this FMEA will be updated
to consider the risk of failures in automatic contouring, and QA techniques will be added to reduce the
risks of these failures.
FMEA is by nature subjective; it incorporates the experience and bias of the team performing it.
Thus, the results of this analysis may not necessarily represent the true risk of the system. Still, FMEA is
a valuable tool for prospectively identifying potential failure modes and risks, which can help to design
QA programs to mitigate the identified risks. Given this limitation, continuous monitoring of the
performance of automated planning tools is vital to the safe use of automated treatment planning.
Moreover, because the RPA is intended for global use in clinics that may have various levels of
resources and follow different practice guidelines, it is important to assess how any deviations from the
procedures and workflows assumed to be in place for this FMEA will affect its evaluations of risk. As
part of initial clinical implementation, the results of this FMEA will be reassessed with multi-disciplinary
teams from each clinic to ensure the results are reflective of each clinics particular risk profile.
Finally, on the basis of the results of this FMEA and the experience we gained through this process,
we identified the following 3 key components of the safe deployment of automated treatment
planning:
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1. Training. Training should educate the end users of automated planning systems about the
potential failure modes, the impact of these failures on patients, and the need for careful
manual review of the plans to prevent these failures.
2. Manual plan checks. Physician review of the plans (and contours, where necessary) and
physics checks are essential components of automated treatment planning.
3. Automated QA. It is important to not only automate the planning, but also to include
automated QA steps, as these can substantially mitigate the risks of automated planning.

5.5 Conclusion
We carried out an FMEA to assess the risk involved in the clinical deployment of automated
treatment planning. We determined that while automated QA reduces the risks of automated planning,
effective training and manual plan checks by radiation oncologists and physicists remain extremely
important parts of the deployment process.
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Chapter 6 : Automated Plan Quality Verification for Cervical Cancer Radiotherapy

6.1 Introduction
The treatment planning process is a primary source of radiation therapy incidents [52], [64]. For
this reason, treatment planning is the focus of many quality assurance (QA) tasks, including physicist
and physician reviews of treatment plans. Reviewing the treatment plan is a time-consuming task, and
although it is considered one of the most effective forms of QA, it still does not reliably catch all errors
that occur in treatment planning [38], [65], [66]. Automating the plan review process would improve
the effectiveness of error detection by drawing reviewers’ attention to aspects of the treatment plan
that are incorrect or are suboptimal and sparing them from reviewing every minute plan detail.
Many radiation therapy groups have already automated various components of the plan review
process. Some automation techniques verify the technical accuracy of the plans (e.g., the consistency of
the prescription, correct settings for the dose calculation, and completeness of physician contouring)
[60], [61], [63], whereas other techniques verify the quality of the treatment plans by comparing them
to physician-specified plan quality objectives, estimated achievable dose metrics, or other similar plans
[62], [67], [68]. The development of techniques to verify plan quality is more subjective and difficult
than the development of techniques to verify the technical accuracy of plans, and most work to date
has focused on the quantitative dose metrics involved in assessing plan quality for advanced
treatments, such as intensity-modulated radiation therapy. However, many clinics rely heavily on
simpler treatment techniques. For example, radiotherapy treatment for patients with cervical cancer
can be delivered through the use of a four-field box with beam apertures based on the bony pelvic
anatomy. This treatment technique is common in resource-constrained settings in which soft-tissue
contouring is not available. In fact, the International Atomic Energy Agency and American Society of
Clinical Oncology recommend that resource-constrained clinics use it to deliver radiotherapy to
patients with cervical cancer [10], [11].
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We have developed a technique to automatically verify the plan quality of three-dimensional
radiation treatments for cervical cancer through detection of clinically unacceptable beam apertures
for the four-field box treatment. The technique involves comparing the planned beam apertures to a
set of independent beam apertures automatically created for the same patient using a secondary
technique. This concept is similar to the concept of verifying dose calculation using a secondary,
independent algorithm to calculate dose for a given patient’s treatment plan.
In this paper, we present our new automated technique for automatically verifying the quality of
beam apertures and describe its application in plans created by a recently developed, fully automated
treatment planning tool intended for use in resource-constrained settings [37], [44]. Because staff is
one of the most limited resources in such clinics [24], any improvement in the efficiency and
effectiveness of QA tasks has a substantial clinical impact.

6.2 Methods and Materials
To detect clinically unacceptable beam apertures, this technique utilizes two independent, fully
automated techniques to generate beam apertures for a single patient’s treatment planning computed
tomography (CT) scan. The beam apertures created using the primary technique are intended to be
used for treatment, and those created using the secondary technique are to be used to verify the
primary treatment apertures. Poor agreement between the two sets of beam apertures indicates that
the treatment beam apertures are potentially clinically unacceptable and can be used to alert the
physician that the beam aperture may be in need of editing. The primary and secondary techniques, as
well as the comparison technique used to detect when the two sets of beam apertures were not in
agreement, are described in the following sections. All patient data used in this study were handled in
accordance with an approved institutional review board protocol.
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6.2.1 Primary Automation Technique for Treatment
The automated planning tool designs four-field box treatments for locally advanced cervical cancer
with beam apertures determined based on a patient’s bony anatomy. The automation technique and
its validation have been previously described elsewhere [37], [44]. In brief, the input to the automated
planning tool is a treatment planning CT scan and a plan directive. First, the marked isocenter and body
contour are automatically defined, and the patient’s bony anatomy is automatically segmented using a
technique that employs deformable registration of multiple atlases [39], [46]. Then, the bony anatomy
is projected into the beam’s-eye-view for each of the four fields, and the beam apertures are
determined based on these projections. Next, the beam apertures are converted into jaws and multileaf collimator (MLC) positions specific to the type of linear accelerator and MLCs to be used for
treatment. Finally, the dose is calculated, and the beam weights are automatically optimized to deliver
a homogenous dose to the treated volume.
In a previous study, two radiation oncologists with expertise in radiotherapy for gynecological
cancers retrospectively reviewed the beam apertures for 150 treatment planning CT scans. These beam
apertures had been generated automatically using the primary technique described above and each
was rated as either “clinically acceptable” or “clinically unacceptable” for treatment. Eighty-nine
percent of the beam apertures were found to be clinically acceptable [44].
6.2.2 Secondary Automation Technique for Verification
For the secondary verification technique, we used the DeepLabv3+ deep learning architecture [69]
to predict the shape of the beam apertures from the digitally reconstructed radiographs (DRRs) for
each beam angle. Essentially, this was a two-dimensional segmentation task in which the deep learning
model was trained to learn which parts of the DRRs should be included in the beam apertures on the
basis of the visible anatomy [70]. The deep learning model was trained and tested on the beam
apertures and DRRs from 310 clinically acceptable four-field box treatment plans (255 for training, 55
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for testing). Physicians had previously reviewed these beam apertures for clinical acceptability as part
of the development and testing of the primary automation technique [44].
During training, 3-fold cross-validation was used to fine-tune the model parameters (learning rate,
decay, etc.). After the optimal parameters were identified during cross-validation, the model was
trained on the complete training set (255 CT scans) for 35 epochs. A single model was trained to
segment all four beams (anteroposterior [AP], posteroanterior [PA], right lateral [RT], and left lateral
[LT]) independently; specifically, the model was trained with an equal distribution of each beam’s DRRs.
To augment the input data, we applied random vertical and horizontal shifts of +/- 5 mm to the input
images. Rotational shifts were investigated but were found to be inappropriate due to the nature of the
beam aperture segmentations (flat edges defined by jaws with no collimator rotations).
After training, the performance of the deep learning model was assessed by comparing the
predicted beam apertures with the ground truth for the 55 test CT scans. The predicted beam apertures
were post-processed prior to comparison in order to impose more typical beam aperture qualities, such
as straight edges at the field borders to replicate the jaw edges. Averaged across all four postprocessed beams for all patients, the mean surface distance (MSD) was 1.6 mm (standard deviation
[SD] = 1.0 mm) and the Hausdorff distance (HD) was 6.6 mm (SD = 4.8 mm) (data not shown). The beam
apertures used in the secondary verification technique were not post-processed, but were the raw
predictions.
6.2.3 Comparison Technique
To detect whether the beam apertures resulting from the primary automation technique were
clinically acceptable, we compared them quantitatively to the beam apertures from the secondary
technique using the following spatial agreement and overlap metrics [39]:
•

MSD: the average Euclidean distance between the points that define the edges of the beam
apertures. A larger MSD indicates worse agreement.
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•

HD: the maximum Euclidean distance between the points that define the edges of the
beam apertures. A larger HD indicates worse agreement.

•

Dice similarity coefficient (DSC): the overlap of the beam apertures as measured by the
ratio of their intersection to their mean area. A DSC value of 1 indicates perfect agreement,
whereas 0 indicates no agreement.

We tested this technique on 320 beam apertures (four apertures from each of 80 treatment plans.
In a previous study, these were rated by physicians with 228 of the beam apertures rated as clinically
acceptable and 92 rated as clinically unacceptable. These plans were part of the cohort used to validate
the automated planning tool for cervical cancer [44]. These CT scans were originally acquired for
treatment planning with the patient in a supine position.
To determine if the beam apertures for the clinically acceptable plans had better agreement with
the secondary technique than those for the clinically unacceptable plans, we compared the values of
the agreement metrics using a one-sided t-test. A p-value of 0.05 was used to determine statistical
significance. We then used a receiver operating characteristic (ROC) analysis to quantify the sensitivity
and specificity with which we could detect unacceptable beam apertures. In this analysis, a true
positive result corresponded to beam apertures that were correctly flagged as unacceptable for
treatment.

6.3 Results
Figure 1, in which each panel corresponds to a different patient, shows examples of the beam
apertures resulting from both automation techniques. Panel A shows a true negative case in which the
two automation techniques agreed and the beam apertures were clinically acceptable. Panels B and C,
show true positive cases in which the two techniques disagreed and the primary beam apertures were
clinically unacceptable. In Panel C, both techniques failed to create clinically acceptable beam
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apertures. Because the two automation techniques use independent methodologies, the disparate
failures successfully flagged the unacceptable beam apertures.
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Figure 14. Examples of Beam Apertures Resulting from Both Automation Techniques. The beam
apertures are shown for the anteroposterior and right lateral beams (left and right images,
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respectively) with results from the primary (red solid line) and secondary (yellow dotted line)
techniques. Panel A shows examples of beam apertures that were correctly classified as clinically
acceptable by the QA technique (a true negative result). Panels B and C show examples of beam
apertures that were correctly classified as clinically unacceptable by the QA technique (true positive
results).
6.3.1 Comparison Metrics
The histogram distributions of the MSD, HD, and DSC values for both clinically acceptable and
unacceptable beam apertures are shown in Figure 15, Figure 16, and Figure 17, respectively. The means
and standard deviations of the comparison metrics tested are embedded in the corresponding figures.
For all comparison metrics, the average agreement was significantly better (lower for MSD and HD,
higher for DSC) for clinically acceptable plans than for clinically unacceptable plans (all p < 0.001). The
histograms show only a small overlap between the two sets of beam apertures.
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Figure 15. Histogram of the Mean Surface Distance (MSD) Values. Comparison of the beam apertures
created by the primary and secondary automation techniques, shown for apertures rated clinically
acceptable (blue) or unacceptable (red) by physicians. In each subfigure, the mean is reported and the
standard deviation is in parentheses for both the acceptable and unacceptable beams. Lower MSD
values indicate better agreement. Abbreviations: AP, anteroposterior; PA, posteroanterior; RT, right
lateral; LT, left lateral.
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Figure 16. Histogram of the Hausdorff Distance (HD) Values. Comparison of the beam apertures created
by the primary and secondary automation techniques, shown for apertures rated clinically acceptable
(blue) or unacceptable (red) by physicians. In each subfigure, the mean is reported and the standard
deviation is in parentheses for both the acceptable and unacceptable beams. Lower HD values indicate
better agreement. Abbreviations: AP, anteroposterior; PA, posteroanterior; RT, right lateral; LT, left
lateral.
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Figure 17. Histogram of the Dice Similarity Coefficient (DSC) Values. Comparison of the beam apertures
created by the primary and secondary automation techniques, shown for apertures rated clinically
acceptable (blue) or unacceptable (red) by physicians. In each subfigure, the mean is reported and the
standard deviation is in parentheses for both the acceptable and unacceptable beams. Higher DSC
values indicate better agreement. Abbreviations: AP, anteroposterior; PA, posteroanterior; RT, right
lateral; LT, left lateral.
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6.3.2 ROC Analysis
Using ROC analysis, we quantified how well each of the comparison metrics could determine if a
beam aperture was unacceptable. The resulting ROC curves for all three metrics are shown in Figure 18.
The area under the curve (AUC) for the AP, PA, RT, and LT beams are also shown (minimum AUC =
0.89). The high AUC values indicate that these comparison metrics could detect unacceptable beam
apertures with good sensitivity and specificity. Overall, the HD metric resulted in the highest AUC for
three of the four beam apertures.

Figure 18. Receiver Operating Characteristic (ROC) Curves for Each Comparison Metric. The area under
the curve (AUC) for each metric and beam angle are shown in the corresponding subfigure.
Abbreviations: AP, anteroposterior; PA, posteroanterior; RT, right lateral; LT, left lateral.
In order to determine a threshold at which to flag plans that may be deemed unacceptable, we
considered two scenarios: one with high sensitivity, giving a true-positive fraction (TPF) of 0.90, and
another with high specificity, giving a low false-positive fraction (FPF) of 0.10. Using the HD metric, we
determined the threshold values and the corresponding FPFs and TPFs for the beams in the highspecificity and high-sensitivity scenarios, respectively (Table 7). For the high-sensitivity scenario, the
corresponding FPF was relatively low, ranging from 0.16 to 0.21. For the high specificity scenario, the
corresponding TPF was relatively high, ranging from 0.74 to 0.87.
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Table 7. HD Thresholds for Two Verification Scenarios.

High sensitivity
(TPF = 0.90)
High specificity
(FPF = 0.10)

Threshold
Corresponding FPF
Threshold
Corresponding TPF

AP Beam

PA Beam

RT Beam

LT Beam

7.0 mm

8.3 mm

14.1 mm

14.1 mm

0.19

0.21

0.16

0.16

11.0 mm

10.4 mm

19.3 mm

19.9 mm

0.87

0.78

0.74

0.74

Abbreviations: HD, Hausdorff Distance; TPF, true-positive fraction; FPF, false-positive fraction; AP,
anteroposterior; PA, posteroanterior; RT, right lateral; LT, left lateral.

6.4 Discussion
In a previous risk assessment of automated treatment planning using failure modes and effects
analysis, it was found that beam aperture creation was one of the high-risk areas subject to failure [71].
Currently, standard practice relies solely on one physician to determine the clinical acceptability of the
beam apertures; there is no secondary check by an independent expert. To our knowledge, the QA
technique presented in this work is the first technique to automatically verify the clinical acceptability
of beam apertures. Because this technique was effective at detecting the clinically unacceptable beam
apertures in need of editing prior to patient treatment with high sensitivity and specificity, it could
make plan reviews more effective without requiring additional effort from staff. The increases in
efficiency and safety wrought by automatic verification could be especially impactful in resourceconstrained settings, where there are immense staff shortages.
We implemented this novel automatic beam aperture verification technique as part of an
automatic QA program that accompanies a fully automated treatment planning tool for cervical cancer
radiotherapy. The goal of the technique is to alert the physician (or other reviewer of plan quality) to
potentially unacceptable beam apertures that, when compared with a secondary set of beam
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apertures, exceed a threshold for a comparison metric. Based on the results of this study, we will
initially use the HD as our comparison metric in our clinically deployed beam aperture verification and
will select a threshold that results in high sensitivity to unacceptable beam apertures. However, this
may result in an excessive number of false positives (i.e., it may create alerts for plans that a physician
would deem acceptable for treatment); in turn, this could cause the alerts to eventually be disregarded.
Accordingly, in the initial clinical deployment of the automated planning tool and QA program, we will
quantify the effectiveness of the automatic verification of beam apertures and solicit feedback from the
physician users regarding the practicality of the thresholds employed for the automatic verification.
By inspecting the plans that were misclassified by the QA technique, we found that most could be
attributed to DRRs that were difficult to interpret. Causes of poor quality DRRs included obscured
anatomy, poor image quality, or high contrast material in the CT scan. An example of a DRR that was
difficult to interpret is shown in Panel C of Figure 1. Poor DRR quality presents a challenge for both the
secondary automation technique, which predicts the beam aperture using the DRR, and for physician
review of the beam apertures via the DRR.
In addition to having utility within the automated planning tool for cervical cancer, the technique
we have presented in this work could be translated to other treatment sites for which beam apertures
are designed automatically or manually using the beam’s eye view. Our group is currently creating such
a tool for use in whole-brain treatments with lateral beams. The methodology presented in this work
can be implemented relatively easily in other clinics wanting to verify the quality of their beam
apertures and to use their existing, clinically approved treatment plans to train the deep learning
model.
With the development and clinical deployment of automated treatment planning, it is natural to
include automated processes that aid the physicist and physician in the review of treatment plans prior
to treatment. However, although automated plan QAs are a useful means of enhancing the QA process
and aiding staff in planning safe and effective radiation treatments, they should only be used for those
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purposes and never as a substitute for final manual reviews by staff. Physicians always have the
responsibility of ensuring that only high-quality plans are approved for treatment. In this study, even
with a threshold set for high sensitivity, 10% of beam apertures rated as clinically unacceptable would
not have been flagged by the QA technique.

6.5 Conclusions
In this work, we tested the ability of a novel beam aperture quality verification technique to detect
clinically unacceptable beam apertures. We found the technique to be very effective, with AUC values
of 0.89-0.95. By comparing the beam apertures with a secondary set that were created using an
independent automated technique, we were able to detect clinically unacceptable beam apertures with
high sensitivity and specificity. This technique will be deployed as part of a fully automated treatment
planning tool for cervical cancer and could be translated to other treatment sites.
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Chapter 7 : Discussion and Conclusion

7.1 Project Summary
The primary objective of this work was to automate radiotherapy treatment planning for patients
with locally advanced cervical cancer and node-positive, postmastectomy breast cancer. Additionally,
we aimed to assess the risk of automated planning and to develop techniques to automatically verify
the quality of automatically-generated treatment plans. To achieve these objectives we first developed
techniques to automate treatment planning for both cervical and breast cancer radiotherapy in
collaboration with hospitals in South Africa and the United States. These automation algorithms were
integrated with a commercial treatment planning system and can generate patient-specific treatment
plans with no further human input once automated planning is initiated. We then validated our
techniques retrospectively by testing these techniques on patient CT scans. Upon physician review of
plans, we found they overwhelmingly accepted the cervical cancer plans as-is (90%) and the remaining
with minor edits (10%). They also accepted the breast cancer plans as-is (50%) or with only minor edits
(50%). Next, we used failure modes and effects analysis (FMEA) to assess the risk involved in the
workflow of using this automated planning tool and demonstrated a shift to lower relative risk when a
quality assurance (QA) program specific to the automated planning tool was included in the analysis.
We then created techniques for automated plan quality verification that were able to successfully
detect potential deviations in plan quality in the automatically planned treatments generated for both
cervical and breast cancer treatments.

7.2 Specific Aim One
In Specific Aim One, we developed and validated a fully automatic treatment planning tool for fourfield box treatments with beam apertures based on bony anatomy, which is the recommended
technique for the delivery of external beam radiotherapy for locally advanced cervical cancer in low75

resource clinics [10], [11]. We developed automation algorithms for the design of the treatment beam
apertures and optimization of the beam weights to minimize dose heterogeneity.
We have validated the clinical acceptability of the treatments planned by our automated planning
tool for cervical cancer in three parts. First, we performed an extensive retrospective validation of the
algorithms developed by testing them using 150 planning CTs. The automatically generated body
contours and marked isocenters agreed well with their manually defined counterparts. In validating the
automatically designed beam apertures, two physicians, one from our institution and one from a South
African partner institution, rated 90.7% and 87.5% of plans acceptable for treatment, respectively. The
use of automatically optimized beam weights significantly reduced the maximum dose while
maintaining coverage within the treated volume. Second, we conducted a successful test of our fully
automated planning tool on-site at two South African hospitals using 14 planning CTs from patients
previously treated at those institutions. Upon physician review of these plans, 100.0% were rated
clinically acceptable. Third, automatically planned treatment beams were clinically deployed at our
institution at have been used for 24 patients with cervical cancer by physicians at our institution, with
edits as needed, and its use is ongoing.
Overall, we have found that the automation techniques developed in this work are effective for
planning patient-specific treatments for locally advanced cervical cancer and may provide a reliable
option for resource-constrained clinics. To our knowledge, this is the first work toward fully automated
treatment planning for radiotherapy of cervical cancer. As cervical cancer is one of the most prevalent
forms of cancer in LMICs, this automated planning tool could help alleviate staff shortages in resourceconstrained clinics. In addition to reducing the workload on staff, another benefit of this automated
planning tool is that patient treatments could be prepared more quickly since the number of handoffs
between physicians and planners would be reduced. This could also improve safety since staff handoffs
is a known weakness in the safety of radiotherapy [42], [43].
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7.3 Specific Aim Two
In Specific Aim Two, we developed and validated a fully automated treatment planning tool for
radiotherapy of the chest wall and ipsilateral lymph nodes using tangential fields matched to an en-face
supraclavicular (SCV) field, a standard treatment for node-positive, post mastectomy breast cancer
patients. Overall, physicians accepted 100% of patient plans with no or minor changes, with 40% of
plans using an alternative match line, which was placed more superior than the clavicular head to
reduce the amount of lung exposed in the SCV field. The major automated steps include (1)
segmentation of relevant structures (targets, normal tissues, and other planning structures); (2) setup
of the beams (tangent fields matched to a supraclavicular field); and (3) optimization of the dose
distribution using a mix of high- and low-energy photon beams and field-in-field modulation for the
tangent fields.
This automated postmastectomy radiation therapy (PMRT) planning tool was tested on ten CT
scans of patients who had previously received radiation to the left chest wall. First we assessed the
accuracy of the automated segmentation of the heart and ipsilateral lung. These contours agreed well
when compared with manually edited contours. Any differences in contouring did not have a
substantial impact on the dose calculated to the organs-at-risk. We then assessed the automatically
created PMRT treatment plans quantitatively and found that they met the acceptable dose objectives,
including target coverage, maximum plan dose, and dose to organs-at-risk, for all patient plans except
for one in which the heart objectives were exceeded. The plans were then reviewed by two physicians
who rated the plans on a three-tier scale: use as-is, minor changes, or major changes. Physicians
accepted the treatment plans for 50% of the plans as-is and required only minor changes for the
remaining 50%.
Given the nuances involved in preparing PMRT and the proximity of the sensitive normal tissues to
the targets, there are many trade-offs that must be balanced in order to achieve the desired final plan
quality. These tradeoffs include covering the target, reducing dose to organs-at-risk, and minimizing the
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maximum dose. As a result, for half of the test patients, physicians would accept the automatically
planned treatments, but would attempt minor changes. This is still a positive outcome given that having
a complete plan that only requires minor changes would likely still result in a substantial reduction in
planning time for these challenging treatments.
To our knowledge, we have developed the first automated planning tool for PMRT and, through
retrospective testing, demonstrated its viability for clinical implementation. This tool has the potential
to improve the efficiency with which we plan these complex treatments. And given the prevalence of
breast cancer in LMICs and the advanced stage at which it is normally diagnosed, this automated PMRT
planning tool can potentially reduce the workload on radiotherapy staff.

7.4 Specific Aim Three
In Specific Aim Three, we first assessed the risk of failure of the automated treatment planning tool
that we have developed using FMEA and demonstrated that a specialized QA program, which included
automatic QA techniques, reduced this risk by improving the detectability of failures. Next, we created
and tested plan quality verification techniques for automatically planned treatments generated in this
work for both cervical and breast cancer treatments which were both more than 90% effective at
detecting potential deviations in plan quality, while having a relatively low false positive rate.
Treatment planning is one of the most error-prone processes in radiation therapy [52], [64]. While
the introduction of automated treatment planning techniques has the potential to reduce this risk, no
formalized assessment of automated planning existed before now. This work has enabled us to
systematically and prospectively identify the highest-risk steps involved in our automated treatment
planning workflow and aided us in developing a specialized QA program. We have found that, while
automated planning is likely a safe process overall, some residual risks persisted, which were similar to
those found in manual treatment planning. Also human error remained a major cause of potential
errors.
78

The risk assessment presented in this work is not only important for the safe clinical
implementation of this automated planning tool, it also has generated broader reaching lessons that
can inform the safe deployment of other automated planning tools. As the prevalence of automated
treatment planning grows, such recommendations for safe deployment will be vital to maintaining
safety for patients treated with radiation therapy. Through this risk analysis process, we identified three
key aspects of safe deployment of automated planning: (1) user training on potential failure modes; (2)
comprehensive manual plan review by physicians and physicists; and (3) automated QA of the
treatment plan.
In the FMEA, beam aperture creation for automated planning for cervical cancer was identified as
one of the higher-risk potential failure modes. This is because the shape of the beam in four-field box
treatments is the main driver of the quality of the treatment plan. As a result, the beam aperture
quality was the focus of the plan quality verification technique developed for automated planning for
locally advanced cervical cancer. We developed a technique to automatically verify the clinical
acceptability of the beam apertures by comparing them with a secondary set of beam apertures
developed using an independent technique. If the two sets of beam apertures disagree, this technique
alerts the user that the beam apertures may need to be edited prior to treatment. We found that our
technique was an effective tool for flagging potentially unacceptable beam apertures during the
treatment plan review process.
This plan quality verification technique is effective because of the total independence of the two
methodologies used for creating the beam apertures. Both methodologies had instances where they
failed to produce acceptable beam apertures, and sometimes this occurred for the same patient.
However, the reason for each methodology failing was different, resulting in different appearances for
the beam apertures, allowing this QA tool to correct flag the unacceptable beam apertures in these
cases.

79

The plan quality verification technique presented in this work is the first to automatically verify
beam apertures. This technique was extremely effective at detecting clinically unacceptable beam
apertures that were in need of editing. Additionally, this technique has applications for radiotherapy of
other treatment sites, including whole-brain treatments. This automated technique could improve the
effectiveness of plan reviews without additional effort from staff, which could improve the efficiency
and safety of the treatment planning QA process.
We also have tested a plan quality verification tool for automatically created PMRT plans that
alerts the user to any possible deviations in the plan quality. Most of these quality verification tests
were based on the plan’s dose distribution. In the testing presented in this work, this tool was able to
detect 92% of the changes requested by physicians. This methodology will be integrated with the
clinical automated planning tool for PMRT, where it could improve the safety of treatment planning by
alerting the physician to potential discrepancies, such as high organ-at-risk dose. These alerts could also
enable quicker adjustment of the treatment plans, if needed, by automatically drawing attention
specifically to the aspect of the treatment plan that may be in need of edit.

7.5 General Discussion
The resulting automated planning tools presented in this work are a consensus based on the
expertise of several physicians from the United States and South Africa and was honed through several
rounds of testing. For cervical cancer, we conducted preliminary testing on more than 250 patient CT
scans. For breast cancer, we conducted preliminary testing on 29 additional patient CT scans prior to
the final test reported in this work.
Through this process, we have become aware of variations in radiotherapy treatment techniques
for similar patients across institutions and physicians. Many of these variations in clinical practice can
likely be accommodated by slight adjustments to the automation algorithms, which have flexibility in
the parameters used to generate the resulting treatment plans (e.g. setting the jaws at 1.5 cm versus
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2.0 cm beyond the widest extent of the pelvis for cervical cancer plans, or alternative superior border
locations for the SCV field of PMRT plans). Such common variations could be accommodated through
the use of institution-specific configuration files containing the preferred techniques. However, if the
variations in clinical practice are too numerous, there is a risk that it becomes impractical to adapt the
algorithms for every new clinic in which the automated planning tool is implemented.
Other variations in treatment plan technique that could easily be accommodated are for patients
with different characteristics than those for which these tools were designed, described in detail in
Appendix A and Appendix B. For example, the automated planning for cervical cancer can be easily
adapted for patients with more extensive nodal disease requiring adjustment of the inferior and/or
superior border locations. For automated planning of breast cancer, the same methodologies can be
used to automatically plan right-sided PMRT, and even for the treatment of intact breast and
treatments without the inclusion of the ipsilateral lymph nodes (SCV and level III axillary). There are
certain variations in radiotherapy technique that would require more extensive changes to the
automation algorithms. One such example would be the treatment of the internal mammary chain
lymph nodes with an en-face electron field, which would require more complex adaptation of the
current algorithms and likely the development of new automation algorithms. Prior to the clinical
implementation of any adaptation of the current automated planning tools, there should be extensive
testing to ensure there are no unexpected outcomes.
The radiotherapy techniques that we selected to automate in this work were based on several
factors including, resource-stratified recommendations from international organizations, the current
clinical practice of our international partner institutions and other institutions in low- and middleincome countries, and the currently available computational techniques for automating the treatment
planning process. As computational techniques progress, it is likely that our ability to automate more
advanced techniques will improve. For example, improved automated segmentation of soft tissues in
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the pelvis would facilitate automated planning of conformal techniques or even inversely-planned
treatment techniques, such as volumetric-modulated arc therapy (VMAT).
The automation of these advanced techniques has the potential to help resource-constrained
clinics transition to more state-of-the-art radiotherapy treatment techniques. In order to make the
transition to more advanced treatments safely, other developments in clinical practice would need to
coincide, including upgraded technology for treatment, new QA processes and equipment, and
additional staff expertise. For example, in order to implement VMAT for cervical cancer, clinics will
need to have external beam radiotherapy machines capable of delivering such treatments, as well as
the equipment necessary to perform the necessary QA tasks. Furthermore, staff will need the expertise
to perform these QA tasks and to be able to sufficiently judge the quality of these treatment plans.

7.6 Study Limitations
A limitation of this study was lack of access to patient data from our partner institution. Due to the
limitations of sharing data across international institutions, it was difficult to have access to large
numbers of patient CT datasets, and especially to the corresponding treatment plans for those patients.
As a result, the large cohort of patient CTs used for testing the automated planning tool for cervical
cancer were from our own institution, with only a small cohort of 14 CT scans used for testing from two
hospitals in South Africa. For automated PMRT planning, we found early in our development that
differences in the position of the arms of patients treated at our institution and our South African
partner institution was hindering the development process. As a result we were only able to conduct
development and testing on data collected from other institutions where the setup was more similar to
our partner institution. This severely limited the number of datasets we were able to use for testing.
Finally, retrospective reviews are a vital step prior to the implementation of any clinical tool
developed. They are useful in gauging the performance of the tool while minimizing interference in
clinical processes. However, they do have several limitations as they do not fully replicate the actual
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clinical conditions in which a physician would normally evaluate the quality of a plan. First, the
physician does not have the extensive patient-specific information that could alter their opinion of the
plan otherwise. Instead, they are instructed to assume the patient is a standard patient (based on the
criteria outline in Appendix A and Appendix B, rather than a special case. Retrospective reviews also
tend to be conducted in a manner in which the physician is reviewing multiple plans consecutively,
which is not typical of the clinic. Prospective reviews in which the physician is comparing the automated
treatment plan to a manually planned treatment, or reviewing and editing a manually planned
treatment prior to patient treatment would give a better indication of the true performance of the
automated planning tools.

7.7 Future Direction
Moving forward, the next step that needs to occur is on-site training and testing with the
prospective end users of the tools for automated planning and plan quality verification. These tools are
in the process of being converted from a standalone research system to a multi-server clinical
implementation that will function as a cloud-based solution. Our partner institutions in southern Africa
and the Philippines can access these tools remotely by submitting approved patient CT scans and
corresponding approved plan directives through specialized user interfaces developed by our research
group [37]. Using these interfaces, they can retrospectively evaluate the performance of these
automated planning tools on larger numbers of their own patient cohorts and even compare the results
of automated planning to the manually planned treatments. All end-users will need to be trained on
the use of the automated planning user interfaces, the appropriate patient characteristics and setup
procedures, and any potential failure modes in automated planning.
Once the prospective end-users have completed retrospective validation of the automated
planning tools, the next step would be for prospective testing with two main goals: evaluating the
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performance under actual clinical conditions and evaluating the reduction in workload and time savings
afforded by automated planning.
Prospective testing can be performed in various ways. One such way is a side-by-side test in which
the treatment plan is generated simultaneously using both automatic and manual planning. Then the
physician would review both plans, ideally blinded to the source of the plan, select their preferred plan,
and give feedback on any discrepancies in the two plans [72]. A benefit of this method is that we could
also collect data on how long each planning method takes and quantify any potential time-savings and
reduction in workload on staff with automated planning. A drawback is that this would require the
physician to evaluate two plans, which would involve more of their limited time during the testing
period. Another way to prospectively test the automated planning is to present the physician with only
the automated plan and then ask them to accept or reject the plan. If accepted, we could then capture
any edits made prior to final approval for patient treatment. The benefit of this method is that it does
not require the physician to review more than one plan. However, it would not allow us to conduct a
head-to-head comparison of the time required for automated and manual planning.
Beyond clinical implementation at our current partner institutions, there are a few other steps that
need to occur to facilitate widespread adoption of these automated planning tools. One such step is the
adaptation of the current versions of the automated planning tools to accommodate more patients
treated for cervical and breast cancer at these institutions. In their current form, the automated tools
only apply to a subset of these patients, although we did select the largest subset based on our
partner’s clinical experience. However, we are still limited by laterality for PMRT and extent of disease
for cervical cancer. With some adaptation, these tools can be adapted to have utility for a majority of
the patients receiving radiotherapy for cervical and breast cancer.
Another step to enable widespread adoption is adapting these automated tools for other clinical
scenarios that are common in resource-constrained clinics. One such example is the lack of access to
high energy photons. These automated tools can be adapted and tested for treatments using only low84

energy photon beams, or even for photon beams generated by Co-60 teletherapy machines. Another
scenarios could be the use of photon blocks rather than MLCs.
Additionally, prior to clinical deployment, the FMEA results should be revisited and updated based
on the final workflow, automation methodologies, and the clinical practice of our partner hospitals
where the tool will be implemented. Any findings that result in higher relative risk should be addressed
by changes in the workflow, training, or other risk mitigation strategies. Through continued use of our
automated planning tools, we can collect quantitative data on the frequency and detectability of any
planning failures, and update the values used in our FMEA. This is similar to the use of an incidentlearning system to inform the results of an FMEA.
The automation tools and techniques developed in this work are part of a larger project with the
long term goal of automating treatment planning for all (or nearly all) radiation treatments. Initially our
work (including that presented here and those of others), have spanned the extent of types of radiation
treatments, from conventional (four-field boxes for cervical cancer) to inversely planned (VMAT for
head-and-neck caner). These techniques build the foundation on which future automated planning
techniques can be developed. For example, the techniques developed for four-field box beam aperture
creation and beam weight optimization can be applied to other sites using this “2.5-D” technique, such
as whole brain treatments using lateral beams or rectal cancer treatments using a three-field belly
board technique. The techniques developed to determine optimal gantry angles for left-sided,
postmastectomy radiotherapy can be used for determine treatment field borders for all types of breast
tangent plans, any treatment using oblique gantry angles, such as the en-face SCV field, and even for
setting up electron beams to treat the internal mammary chain lymph nodes. Additionally, the
techniques developed for automating the optimization of the dose distribution using mixed energy
photon beams and field-in-field segments could be applied to any radiation treatment using field-infield style modulation to achieve more homogenous dose distributions.
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7.8 Conclusion
For automated planning for locally advanced cervical cancer, radiation oncologists accepted as-is
89.6% of treatments plans reviewed in the two test cohorts, with three expert physicians evaluating
different subsets of the plans. The remaining 10% required only minor changes in the beam apertures.
For node-positive, postmastectomy breast cancer, 100% of the plans were accepted with no or only
minor changes and are therefore considered clinically viable. Therefore, our hypothesis that 90% of the
treatment plans created with our automated planning techniques would be rated as clinically
acceptable by radiation oncologists was proven in this work. Furthermore, the techniques we
developed for the automated detection of poor quality beam apertures for cervical cancer radiotherapy
was able to detect 90% of the unacceptable beam apertures with good specificity. The automated
detection of deviations in plan quality for PMRT treatments detected 92% of the changes requested by
radiation oncologists. Therefore, our hypothesis that our automated quality verification techniques
would detect 90% of unacceptable plans was proven in this work.
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Appendix A
Statement of appropriate use of the automated planning tool for cervical cancer
The automated planning tool developed in this work for radiotherapy of locally advanced cervical
cancer has been designed and tested for a certain disease extent, treatment setup, treatment
technique. Below are a list of criteria relating to the appropriate use of the current version of the
automated planning tool presented in this work. Applicability of this tool to other similar conditions are
feasible but not yet vetted.

Patient Disease Extent
•

Locally advanced cervical cancer

•

Disease limited to the upper two-thirds of the vagina (ie, not involving the distal vagina)

•

Disease only involving the pelvic lymph node (eg, not involving the paraaortic lymph nodes).

Patient Treatment Setup
•

Head first, supine

•

Marked and treatment isocenter indicated with a three-point external fiducial setup

•

No additional high density objects (eg, wires or fiducials) should be placed on the patient’s
body surface

•

No intravenous or oral contrast should be used in the planning CT scan

Treatment Technique
•

Four-field box treatment technique with beam apertures based on bony anatomy

•

Delivered using a linear accelerator with high energy photons

•

Treatment fields defined by asymmetrical jaws and MLCs (ie, no photon blocks)
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•

Dose normalized 100% to the marked/treatment isocenter

AP and PA Beam Aperture Description
Table 8. The AP and PA beams are not mirror images of each other. The location of each jaw or block
described below is indicated by the Roman numeral and corresponds to the location shown in panel A
of Figure 19.

Superior-right block (i)

From transverse process, straight line to level of SI (sacroiliac) joint
(where sacrum touches the pelvis, ie, the top of the pelvic inlet)

Superior jaw (ii)

L3/L4 (ie, top of L4)

Superior-left block (iii)

From transverse process, straight line to level of SI (sacroiliac) joint
(where sacrum touches the pelvis, ie, the top of the pelvic inlet)

Left jaw (iv)

2.0 cm from widest part of pelvic inlet

Inferior-left block (v)

From where the top of the femoral head crosses the jaw, a straight
line to skirt past the obturator foramen. Make sure to not block the
medial/superior aspect of the femoral head

Inferior jaw (vi)

Bottom of the pelvis

Inferior-right block (vii)

From where the top of the femoral head crosses the jaw, a straight
line to skirt past the obturator foramen. Make sure to not block the
medial/superior aspect of the femoral head

Right jaw (viii)

2.0 cm from widest part of pelvic inlet
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Lateral Beam Aperture Description
Table 9. The right and left lateral beams are mirror images of each other. The location of each jaw or
block described below is indicated by the Roman numeral and corresponds to the location shown in
panel B of Figure 19.

Superior-posterior block (i)

Follow curve of vertebral bodies

Superior jaw (ii)

L3/L4 (ie, top of L4)

Superior-anterior block (iii)

Start 3.5 cm out anterior to the vertebral bodies then straight
inferior till bottom of L5. From there, diagonal out till anterior jaw,
the slope of which is parallel to the slope from S1/L5 to top of
pubic symphysis

Anterior jaw (iv)

Anterior to the pubic symphysis by 0.5 cm. However, if this puts
the jaw <3.5 cm anterior to the vertebral bodies, then set at 3.5 cm
anterior to the vertebral bodies.

Inferior-anterior block (v)

Following just inferior to the pubic symphysis

Inferior jaw (vi)

Bottom of the pelvis

Inferior-posterior block (vii)

Start at posterior jaw at level of coccyx. Follow the curve of the
coccyx and draw a curved line toward where the pelvis crosses the
inferior jaw

Posterior jaw (viii)

Posterior to the sacrum
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Figure 19. Figure adapted from Kisling et al [44]. Beam’s eye view of the (A) anteroposterior (AP) and
(B) right lateral beam angles. The Roman numerals indicate the location of a jaw or block which
corresponds to the descriptions above in Table 8 and Table 9.
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Appendix B
Statement of appropriate use of the automated planning tool for breast cancer
The automated planning tool developed in this work for radiotherapy of node-positive,
postmastectomy breast cancer has been designed and tested for a certain disease extent, treatment
setup, treatment technique. Below are a list of criteria relating to the appropriate use of the current
version of the automated planning tool presented in this work. Applicability of this tool to other similar
conditions are feasible but not yet vetted.

Patient Disease Extent
•

Node-positive, postmastectomy breast cancer requiring treatment of the chest wall,
supraclavicular (SCV) lymph nodes, and level III axillary lymph nodes

•

For treatment of left-sided disease only

•

Not for treatment of the internal mammary chain lymph nodes

•

Not for patients with skin involvement

Patient Treatment Setup
•

Head first, supine

•

Both arms raised over the patient’s head

•

Patient scanned while freely breathing (ie, no deep inspiration breathhold)

•

Patient positioned on an angled breast board

•

Marked isocenter indicated with a three-point external fiducial setup

•

No intravenous or oral contrast should be used in the planning CT scan
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Treatment Technique
•

Monoisocentric medial and lateral tangential fields matched to an oblique, en-face
supraclavicular field

•

Designed for a hypofractionated treatment (40.05 Gy in 15 fractions)

•

Delivered using a linear accelerator with both low and high energy photons (specifically 6 MV
and 18 MV)

•

Treatment fields defined by asymmetrical jaws and MLCs (ie, no photon blocks)

•

Mixed energies allowed for all fields

•

Up to two field-in-field segments per medial and lateral tangential beam

•

Match line between tangential and SCV fields is placed at the inferior extent of the clavicle
o

If the tangent fields are too long (>20 cm maximum field size for a half-beam blocked
field for Varian C-arm machines, such as 2100 series or TrueBeam), the match line if
moved more inferior

o

If there is insufficient open field inferior to the humeral head (<2 cm), the match line if
moved more inferior

o

If there is too much lung in the SCV field (>4 cm from the inferior border of field to the
apex of the lung in the beam’s eye view), the match line is moved more superior (as
long as the previous two points allow this move)

Tangential Field Description
•

A beam’s eye view of an example of the medial tangential field is shown in Figure 20. The
location of each border described below is indicated by a Roman numeral that corresponds to
the location shown in the figure.

•

The collimator angle is 0 degrees

•

The superior border (i) is at the match line location
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•

The inferior border (ii) is 1 cm below the most inferior extent of the breast tissue (which is
manually identified)

•

The anterior border (iii) allows for 2 cm of flash

•

The posterior border (iv) is defined by the MLCs

Figure 20. Beam’s eye view of the medial tangential field. The Roman numerals indicate the location of
a border that corresponds to the descriptions of the field.

SCV Field Description
•

A beam’s eye view of an example of the SCV field is shown in Figure 21. The location of each
border described below is indicated by a Roman numeral that corresponds to the location
shown in the figure.

•

The superior border (i) is at the cricoid

•

The inferior border (ii) is at the match line location

•

The medial border (iii) shields the esophagus and spinal cord

•

At the lateral border of the field (iv), the humeral head is shielded
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Figure 21. Beam’s eye view of the SCV field. The Roman numerals indicate the location of a border that
corresponds to the descriptions of the field.

Dosimetric Goals
Table 10. These objectives were determined using several sources, including objectives from a
hypofractionated PMRT clinical trial (unpublished protocol) [49], recommendations from The Royal
College of Radiologists [45], and clinical objectives from our partner hospitals.
Region of Interest

Dose Metric

Preferred Objective

Acceptable Limit

Mean Dose

< 4 Gy

< 6 Gy

Volume > 25 Gy

< 7%

< 10%

Volume > 17 Gy

< 35%

< 40%

Heart

Ipsilateral (left) lung

94

Appendix C
Full results of failure modes and effects (FMEA) analysis
Table 11. The following table contains the potential failure mode and potential cause of failure for each
process step assessed in the Radiation Planning Assistant (RPA) workflow (depicted in Figure 11 in
Chapter 5). The FMEA scores are shown for the likelihood of occurrence (O), severity (S), likelihood of
going undetected (D), and the overall risk priority number (RPN) both without and with the specialized
quality assurance (QA) program.

Without QA
program
Process
Step

Process Step
Description

Potential Failure
Mode

Potential Cause of
Failure

O

S

D

1

CT simulation

1.01

Position patient

Incorrect orientation

Human error

3

9

2

54

1.01

Position patient

Incorrect orientation

Standard
technique varies
from RPA protocol

6

9

3

1.01

Position patient

Incorrect orientation

Intentional nonstandard technique

4

9

1.01

Position patient

Unexpected
immobilization (that
affects CT data)

Human error

3

1.01

Position patient

Unexpected
immobilization (that
affects CT data)

New
immobilization
device

1.01

Position patient

Unexpected
immobilization (that
affects CT data)

1.01

Position patient

1.01

With QA program

RPN O

S

D

RPN

3

9

2

54

162

6

9

1

54

3

108

4

9

2

72

5

8

120

3

5

6

90

2

5

7

70

2

5

6

60

Standard
technique varies
from RPA protocol

3

5

8

120

3

5

7

105

Unexpected
immobilization (that
affects CT data)

Intentional nonstandard technique

4

5

8

160

4

5

6

120

Position patient

Inappropriate
positioning (eg arm
in-field)

Human error

6

4

7

168

6

4

7

168

1.01

Position patient

Inappropriate
positioning (eg arm
in-field)

Intentional nonstandard technique

4

4

8

128

4

4

8

128

1.02

Place external
fiducials

Inappropriate type of
external fiducials

Human error

2

4

8

64

2

4

4

32

95

1.02

Place external
fiducials

Inappropriate type of
external fiducials

Standard
technique varies
from RPA protocol

2

4

8

64

2

4

4

32

1.02

Place external
fiducials

External fiducials
exceed planar
limitations

Human error

3

3

1

9

3

3

1

9

1.02

Place external
fiducials

External fiducials
exceed planar
limitations

Patient moves

4

3

1

12

4

3

1

12

1.02

Place external
fiducials

<3 external fiducials
placed

Human error

1

3

1

3

1

3

1

3

1.02

Place external
fiducials

<3 external fiducials
placed

Standard
technique varies
from RPA protocol

8

3

1

24

8

3

1

24

1.02

Place external
fiducials

<3 external fiducials
placed

External fiducials
fall off

2

3

1

6

2

3

1

6

1.02

Place external
fiducials

Out of range of
treatment/wrong
location

Human error

3

6

4

72

3

6

2

36

1.03

Enter patient
information

Incorrect ID or name

Human error

2

1

1

2

2

1

1

2

1.03

Enter patient
information

Incorrect ID or name

Human error

1

10

9

90

1

10

9

90

1.04

Select CT
protocol and
execute

Orientation entered
incorrectly

Human error

5

2

1

10

5

2

1

10

1.04

Select CT
protocol and
execute

Orientation entered
incorrectly

Standard
technique varies
from RPA protocol

5

2

1

10

5

2

1

10

1.04

Select CT
protocol and
execute

Orientation entered
incorrectly

Incorrect CT
protocol selected
(eg HN protocol)

5

2

1

10

5

2

1

10

1.04

Select CT
protocol and
execute

Orientation entered
incorrectly

Standard CT
protocol is
inappropriate

5

2

1

10

5

2

1

10

1.04

Select CT
protocol and
execute

Too large slice
spacing

Human error

2

8

5

80

2

8

3

48

1.04

Select CT
protocol and
execute

Too large slice
spacing

Standard
technique varies
from RPA protocol

2

8

5

80

2

8

3

48

1.04

Select CT
protocol and
execute

Too large slice
spacing

Incorrect CT
protocol selected
(eg HN protocol)

2

8

5

80

2

8

3

48

1.04

Select CT
protocol and
execute

Too large slice
spacing

Standard CT
protocol is
inappropriate

2

8

5

80

2

8

3

48

96

1.04

Select CT
protocol and
execute

FOV is too small

Human error

5

8

7

280

5

8

6

240

1.04

Select CT
protocol and
execute

FOV is too small

Patient is too large

5

8

7

280

5

8

6

240

1.04

Select CT
protocol and
execute

FOV is too small

Incorrect CT
protocol selected
(eg HN protocol)

3

8

7

168

3

8

6

144

1.04

Select CT
protocol and
execute

FOV is too small

Standard CT
protocol is
inappropriate

2

8

7

112

2

8

6

96

1.04

Select CT
protocol and
execute

Insufficient scan
length

Human error

4

3

1

12

4

3

1

12

1.04

Select CT
protocol and
execute

kV/mA inappropriate
(affects image
quality)

Human error

1

5

5

25

1

5

5

25

1.04

Select CT
protocol and
execute

kV/mA inappropriate
(affects image
quality)

Incorrect CT
protocol selected
(eg HN protocol)

1

5

5

25

1

5

5

25

1.04

Select CT
protocol and
execute

kV/mA inappropriate
(affects image
quality)

Standard CT
protocol is
inappropriate

1

5

5

25

1

5

5

25

1.04

Select CT
protocol and
execute

Used contrast (IV or
oral)

Human error

3

5

5

75

3

5

3

45

1.04

Select CT
protocol and
execute

Used contrast (IV or
oral)

Standard
technique varies
from RPA protocol

8

5

5

200

8

5

3

120

1.04

Select CT
protocol and
execute

Used contrast (IV or
oral)

Intentional nonstandard technique

4

5

5

100

4

5

3

60

1.04

Select CT
protocol and
execute

Scan
incomplete/failure

Power failure

1

3

1

3

1

3

1

3

1.04

Select CT
protocol and
execute

Scan
incomplete/failure

Patient issues

1

3

1

3

1

3

1

3

1.05

Transfer CT to
RPA control
center

Incorrect CT sent

Human error

4

4

8

128

4

4

8

128

1.05

Transfer CT to
RPA control
center

Data
corrupted/incomplete

Network error

1

7

5

35

1

7

3

21

1.05

Transfer CT to
RPA control
center

Data
corrupted/incomplete

Human error (too
quick)

6

7

5

210

6

7

3

126

97

1.05

Transfer CT to
RPA control
center

Not completed

Network error

1

2

1

2

1

2

1

2

1.05

Transfer CT to
RPA control
center

Not completed

Human error

3

2

1

6

3

2

1

6

1.06

Approve CT in
RPA control
center

Not approved

Human error

8

2

1

16

8

2

1

16

1.06

Approve CT in
RPA control
center

Approve incorrect CT
(same patient, if >1
CT)

Human error

3

4

8

96

3

4

8

96

1.07

Transfer CT from
RPA control
center to RPA
planning module

Data corrupted

Network error

1

7

5

35

1

7

3

21

1.07

Transfer CT from
RPA control
center to RPA
planning module

Not completed

Network error

1

2

1

2

1

2

1

2

2

Plan directive

2.01

Enter patient
information

Incorrect ID or name

Human error

2

10

1

20

2

10

1

20

2.01

Enter patient
information

Incorrect ID or name

Human error

2

1

1

2

2

1

1

2

2.01

Enter patient
information

Incomplete ID or
name

Human error

2

1

1

2

2

1

1

2

2.01

Enter patient
information

Incompatible digits

Algorithm error

2

1

1

2

2

1

1

2

2.02

Enter treatment
site

Incorrect treatment
site

Human error

3

1

1

3

3

1

1

3

2.02

Enter treatment
site

Not completed

Human error

2

1

1

2

2

1

1

2

2.03

Questions about
patient
appropriateness

Not completed

Human error

2

1

1

2

2

1

1

2

2.03

Questions about
patient
appropriateness

Completed
incorrectly

Human error

2

9

7

126

2

9

7

126

2.03

Questions about
patient
appropriateness

Completed
incorrectly

Human error

4

9

5

180

4

9

5

180

2.04

Enter
prescription

Incorrect dose (not
changed from
default)

Human error

4

9

7

252

4

9

7

252

2.04

Enter
prescription

Incorrect dose
(changed from
default incorrectly)

Human error

3

9

6

162

3

9

6

162

98

2.05

Select treatment
machine

Incorrect

Human error

6

3

6

108

6

3

6

108

2.05

Select treatment
machine

Not selected

Human error

2

1

1

2

2

1

1

2

2.06

Approve plan
directive

Not completed

Human error

2

1

1

2

2

1

1

2

2.06

Approve plan
directive

Approved by staff
without correct rights

Shared
login/incorrect
rights

4

9

5

180

4

9

5

180

2.07

Data transfer
from RPA control
center to RPA
planning module

Data corrupted

Network error

2

1

1

2

2

1

1

2

2.07

Data transfer
from RPA control
center to RPA
planning module

Not completed

Network error

2

1

1

2

2

1

1

2

3

RPA plan
creation

3.01

Isocenter
position

Incorrectly identified

Other external
fiducials

7

9

8

504

7

9

5

315

3.01

Isocenter
position

Incorrectly identified

Out of range of CT
scan

3

9

8

216

3

9

4

108

3.01

Isocenter
position

Incorrectly identified

Algorithm error

4

9

8

288

4

9

4

144

3.01

Isocenter
position

Not identified

Out of range of CT
scan

3

2

1

6

3

2

1

6

3.01

Isocenter
position

Not identified

Algorithm error

2

2

1

4

2

2

1

4

3.02

Body contour

Inadequately
contoured

Inappropriate
immobilization

5

5

8

200

5

5

6

150

3.02

Body contour

Inadequately
contoured

Poor image quality

5

4

8

160

5

4

5

100

3.02

Body contour

Inadequately
contoured

Unexpected item
in CT (eg arm, cell
phone, etc)

6

4

7

168

6

4

5

120

3.02

Body contour

Inadequately
contoured

Unexpected couch
(eg low density
material)

3

4

8

96

3

4

6

72

3.02

Body contour

Inadequately
contoured

Algorithm error

4

5

8

160

4

5

4

80

3.02

Body contour

Not created

Algorithm error

2

2

1

4

2

2

1

4

3.03

All 4 beams
created

Not at isocenter

Algorithm error
before aperture
creation

1

9

8

72

1

9

6

54

99

3.03

All 4 beams
created

Not at isocenter

Algorithm error
after aperture
creation

1

9

5

45

1

9

2

18

3.03

All 4 beams
created

<4 beams created

Algorithm error

1

2

1

2

1

2

1

2

3.03

All 4 beams
created

Wrong machine

Algorithm error

1

4

5

20

1

4

5

20

3.04

Gantry angles

Incorrect

Algorithm
error/corrupted
template

1

5

8

40

1

5

6

30

3.05

Collimator angle
=0

Incorrect

Algorithm
error/corrupted
template

1

5

5

25

1

5

3

15

3.06

Couch angle = 0

Incorrect

Algorithm
error/corrupted
template

1

5

7

35

1

5

5

25

3.07

Jaw positions

Inappropriate
position

Poor image quality

5

5

5

125

5

5

4

100

3.07

Jaw positions

Inappropriate
position

Algorithm error

10

7

6

420 10

7

4

280

3.07

Jaw positions

Inappropriate
position

Presence of high
contrast material

8

5

5

200

8

5

4

160

3.07

Jaw positions

Inappropriate
position

Unexpected item
in CT (eg arm, cell
phone, etc)

6

4

7

168

6

4

6

144

3.07

Jaw positions

Inappropriate
position

Isocenter at
extreme location

6

6

5

180

6

6

3

108

3.07

Jaw positions

Exceeds delivery
limits

Algorithm error

7

2

1

14

7

2

1

14

3.08

MLC positions

Inappropriate
position

Poor image quality

5

5

5

125

5

5

4

100

3.08

MLC positions

Inappropriate
position

Algorithm error

10

7

6

420 10

7

4

280

3.08

MLC positions

Inappropriate
position

Presence of high
contrast material

8

5

5

200

8

5

4

160

3.08

MLC positions

Inappropriate
position

Unexpected item
in CT (eg arm, cell
phone, etc)

6

4

7

168

6

4

6

144

3.08

MLC positions

Inappropriate
position

Isocenter at
extreme location

6

6

5

180

6

6

3

108

3.08

MLC positions

Not present

Algorithm error

1

9

3

27

1

9

2

18

3.08

MLC positions

Exceeds delivery
limits

Algorithm error

7

2

1

14

7

2

1

14

3.09

Accessories set

Incorrect

Algorithm
error/corrupted
template

1

7

4

28

1

7

2

14

100

3.10

Prescription set

Incorrect (doesn't
match plan directive

Algorithm error

1

10

7

70

1

10

5

50

3.10

Prescription set

Incorrect
normalization

Algorithm
error/corrupted
template

1

10

7

70

1

10

5

50

3.11

Energy set

Incorrect energy

Algorithm
error/corrupted
template

1

4

8

32

1

4

6

24

3.12

Dose distribution

Calculation point is
inappopriate

Located in high or
low CT number

10

4

6

240 10

4

3

120

3.12

Dose distribution

Incorrect but
approved calculation
algorithm

Algorithm error

1

1

10

10

1

1

9

9

3.12

Dose distribution

No heterogeneity
correction

Algorithm error

1

4

8

32

1

4

6

24

3.12

Dose distribution

Dose grid
inappropriate
(size/location)

Algorithm error

1

4

6

24

1

4

4

16

3.12

Dose distribution

Calculation point is
not at isocenter

Algorithm error

1

10

7

70

1

10

5

50

3.13

Field weights set

Inappropriate

Algorithm error

5

4

8

160

5

4

7

140

3.14

Plan
documentation

Data corrupted

Algorithm error

3

10

4

120

3

10

4

120

3.14

Plan
documentation

Not created

Algorithm error

1

2

1

2

1

2

1

2

4

Plan approval

4.01

Physician plan
review

Not completed

Human error

2

3

1

6

2

3

1

6

4.01

Physician plan
review

No comprehensive
review

Human error

3

10 10 300

3

10 10 300

4.02

Data transfer
from RPA to
local TPS

Not completed

Network error

3

3

1

9

3

3

1

9

4.02

Data transfer
from RPA to
local TPS

Data corrupted

Network error

2

10

5

100

2

10

3

60
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Appendix D
Quality assurance (QA) for the location of the calculation point in four-field box treatment
plans for cervical cancer radiotherapy
In the automated planning tool for cervical cancer radiotherapy that was developed in this work,
the calculation point is set at the location of the marked isocenter, per the local practice of our partner
hospitals located in low- and middle-income countries. This calculation point is used as the prescription
point, where the dose is set to be normalized to 100% of the prescription, and as the reference point
for the relative field weights.
In our testing of automated planning for cervical cancer radiotherapy, we discovered that
sometimes the location of the calculation point was not suitable to be used for dose calculation. There
were two main causes: (1) the calculation point was very close to the edge of the treatment field and
(2) the calculation point was located in high density material, such as bone, or low density material,
such as gas within the bowels.
In order to avoid creating treatment plans with an inadequate location for the calculation point, we
developed an automatic QA test of the location of the calculation point. The first QA test was based on
the proximity of the calculation point to the edge of the treatment field and creates a flag if the
proximity is less than 2 cm. In a test of 366 patient plans, 1.1% were found to have the calculation point
located within 2 cm of the edge of at least one beam aperture.
The second QA test is based on the distribution of the CT numbers in the region around the
calculation point. This QA test evaluates a 1-cm radius sphere around the calculation point and
searches for high-density by assessing the 90th percentile of the CT numbers within this sphere (ie, the
most dense values) and searches for low-density by assessing the 10th percentile of the CT numbers
within this sphere (ie, the least dense values). In a test of 366 patient plans, using an upper threshold of
200 and a lower threshold of -200 created flags for 5.7% and 9.6% of patient plans, respectively. The
distributions of the CT number at the 90th and 10th percentiles for these patients are shown in Figure 22
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below. The red line indicates the threshold value used in this test. Examples of patient plans that were
flagged for high and low density are shown in Figure 23.

Figure 22. Histogram of the 90th percentile (left) and 10th percentile (right) of the CT numbers within a
1-cm radius sphere around the calculation point for 366 patient plans. The red line indicates a threshold
that was used in a QA test of the location of the calculation point.

Figure 23. Examples of patient plans that were flagged for high and low density (left and right,
respectively). The plan flagged for high density had a CT number of 548 at the 90th percentile, and the
plan flagged for low density had a CT number of -375 at the 10th percentile.
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